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Abstract 
Background & AIMS: To improve the clinical course of ulcerative colitis (UC), more accurate 
serum diagnostic and assessment methods are required. We used serum metabolomics to 
develop diagnostic and assessment methods for UC. 
Methods: Sera from UC patients, Crohn’s disease (CD) patients, and healthy volunteers (HV) 
were collected at multiple institutions. The UC and HV were randomly allocated to the training 
or validation set, and their serum metabolites were analyzed by gas chromatography mass 
spectrometry (GC/MS). Using the training set, diagnostic and assessment models for UC 
were established by multiple logistic regression analysis. Then, the models were assessed 
using the validation set. Additionally, to establish a diagnostic model for discriminating UC 
from CD, the CD patients’ data were used. 
Results: The diagnostic model for discriminating UC from HV demonstrated an AUC of 0.988, 
93.33% sensitivity, and 95.00% specificity in the training set and 95.00% sensitivity and 
98.33% specificity in the validation set. Another model for discriminating UC from CD 
exhibited an AUC of 0.965, 85.00% sensitivity, and 97.44% specificity in the training set and 
83.33% sensitivity in the validation set. The model for assessing UC showed an AUC of 0.967, 
84.62% sensitivity, and 88.23% specificity in the training set and 84.62% sensitivity, 91.18% 
specificity, and a significant correlation with the clinical activity index (rs=0.7371, P<0.0001) in 
the validation set. 
Conclusions: Our models demonstrated high performance and might lead to the 
development of a novel treatment selection method based on UC condition.  
Keywords: ulcerative colitis; metabolomics; GC/MS; multiple logistic regression analysis; 
biomarker 
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Introduction 
Inflammatory bowel disease (IBD) involves chronic and recurring inflammation of 
the gastrointestinal tract and is composed of two major subtypes, ulcerative colitis (UC) and 
Crohn’s disease (CD). The incidence rates of IBD are increasing in several industrialized 
countries, especially Asian-Pacific countries in which the population’s lifestyle has become 
more westernized, e.g., Japan (1). Previous studies have suggested that these increases in 
the incidence of IBD are associated with immunological disorders caused by genetic, 
environmental, and microbiological factors (2,3), and environmental factors are probably the 
main causes of these increases because it is unlikely that the genetic background of the 
people in these countries has changed markedly within a few decades (4,5). However, the 
etiology of IBD remains to be understood, and therefore, disease-specific treatments and 
diagnostic methods for IBD have yet to be established. At present, comprehensive diagnostic 
criteria based on clinical, endoscopic, histological, and radiological findings are used to 
diagnose IBD, but it is difficult to distinguish CD from UC in approximately 2-15% of IBD 
cases, and these cases are treated as indeterminate colitis (IC) (6-8). Recently, a 
combination of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) and 
anti-Saccharomyces cerevisiae antibodies (ASCA) was demonstrated to be a useful 
biomarker for discriminating between the different types of IBD (9), but such serological 
markers are not suitable for clinical application because of their low sensitivity/specificity. 
 Recently, IBD has started to be evaluated via proteomics and metabolomics-based 
methods involving nuclear magnetic resonance spectroscopy (NMR), surface enhanced laser 
desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS), matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), gas 
chromatography mass spectrometry (GC/MS), and/or liquid chromatography mass 
spectrometry (LC/MS) (10-14). In this study, metabolomics was used to investigate the 
alterations in the serum metabolite profiles of IBD patients. Metabolomics is a comprehensive 
method and is capable of evaluating the characteristics of and interactions between the low 
molecular weight metabolites of a cell, tissue, organ, or organism. Metabolites are located at 
the endpoint of the omics cascade; i.e., the last step before the phenotype, and therefore, 
metabolite profiles might represent the expression patterns of regulatory factors. Thus, 
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studying such profiles might allow the pathology of IBD to be elucidated in more detail. In our 
previous reports, it was demonstrated that a serum metabolite profile consisting of amino 
acids and tricarboxylic acid cycle (TCA)-related metabolites was able to discriminate among 
UC patients, CD patients, and healthy volunteers (15, 16), although the study only involved a 
small number of samples. Therefore, in the present study an increased number of samples 
were used, and both training and validation sets were employed. Using a training set 
composed of UC patients (N=60) and healthy volunteers (N=60), diagnostic and assessment 
models for UC were established by selecting candidate metabolites using the volcano plot 
and stepwise methods and then subjecting them to multiple logistic regression analysis. Then, 
the validity of the resultant predictive models was assessed using a validation set consisting 
of UC patients (N=60) and healthy volunteers (N=60). In addition, to establish a diagnostic 
model for discriminating UC from CD and to validate the diagnostic model for discriminating 
UC from HV, CD patients’ (N=39) data were used as a training set and additional validation 
set. 
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Materials and Methods 
Patients 
This study was approved by the ethics committees at Kobe University Graduate 
School of Medicine (Hyogo, Japan) and Hyogo Medical University (Hyogo, Japan) and was 
performed between February 2009 and February 2013. The human samples were used in 
accordance with the guidelines of each hospital, and written informed consent was obtained 
from all subjects. The serum samples from the IBD patients (N=159), UC patients (N=120), 
and CD patients (N=39) were collected at Kobe University Hospital and Hyogo Medical 
University. UC and CD were diagnosed according to relevant criteria based on clinical 
symptoms, and radiographic, endoscopic, and pathological findings. Disease activity was 
assessed using the Crohn’s disease activity index (CDAI) (17) and Rachmilewitz index [a 
clinical activity index (CAI)] (18). Active disease was defined as a CDAI of ≥150 for CD and a 
CAI of ≥ 6 for UC. Remission was defined as a CDAI of <150 for CD and a CAI of <6 for UC. 
The serum samples from the HV (N=120) were collected at Aijinkai Chibune General Hospital 
(Osaka, Japan) and Shinkokai Shinko Hospital Health Examination Center (Hyogo, Japan). 
No clinical abnormalities were detected in the HV during medical check-ups involving physical, 
blood, urine, imaging, and/or endoscopic examinations. 
 
Serum collection and preparation 
Each whole blood sample was collected in a clean tube and immediately centrifuged 
at 3,000 x g for 10 min at 4ºC. Then, the serum was transferred to a clean tube and stored at 
-80ºC until use. The extraction of low molecular weight metabolites was performed according 
to the method described in our previous report (19). Briefly, 50 μl of serum were mixed with 
250 μl of a solvent mixture (MeOH:H2O:CHCl3=2.5:1:1) containing 10 μl of 0.5 mg/ml 
2-isopropylmalic acid (Sigma-Aldrich, Tokyo, Japan) dissolved in distilled water as an internal 
standard, and then the solution was shaken at 1,200 rpm for 30 min at 37°C, before being 
centrifuged at 16,000 x g for 3 min at 4°C. Two hundred and twenty-five μl of the resultant 
supernatant were transferred to a clean tube, and 200 μl of distilled water were added to the 
tube. After being mixed, the solution was centrifuged at 16,000 x g for 3 min at 4°C, and 250 
μl of the resultant supernatant were transferred to a clean tube, before being lyophilized using 
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a freeze dryer. For oximation, 40 μl of 20 mg/ml methoxyamine hydrochloride (Sigma-Aldrich) 
dissolved in pyridine were mixed with a lyophilized sample, which was then shaken at 1,200 
rpm for 90 min at 30°C. Next, 20 μl of N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) 
(GL Science, Tokyo, Japan) were added for derivatization, and the mixture was incubated at 
1,200 rpm for 30 min at 37°C. The mixture was then centrifuged at 16,000 x g for 5 min at 4°C, 
and the resultant supernatant was subjected to GC/MS measurement. 
 
GC/MS analysis 
According to the method described in a previous report (20), the GC/MS analysis 
was performed using a GCMS-QP2010 Ultra (Shimadzu Co., Kyoto, Japan) with a fused 
silica capillary column (CP-SIL 8 CB low bleed/MS; inner diameter: 30 m × 0.25 mm, film 
thickness: 0.25 μm; Agilent Co., Palo Alto, CA). The front inlet temperature was 230°C, and 
the flow rate of helium gas through the column was 39.0 cm/sec. The column temperature 
was held at 80°C for 2 min and then raised by 15°C/min to 330°C and held there for 6 min. 
The transfer line and ion-source temperatures were 250°C and 200°C, respectively. Twenty 
scans per second were recorded over the mass range 85-500 m/z using the Advanced 
Scanning Speed Protocol (ASSP, Shimadzu Co.). 
 
Data processing 
Data processing was performed according to the methods described in previous 
reports (20,21). Briefly, the MS data were exported in netCDF format. The peak detection and 
alignment were performed using the MetAlign software (Wageningen UR, The Netherlands). 
The resultant data were exported in CSV format and then analyzed with in-house analytical 
software (AIoutput) and an in-house metabolite library for peak identification and 
semi-quantitative analysis. For the semi-quantitative analysis, the peak height of each ion 
was calculated and normalized to the peak height of 2-isopropylmalic acid as an internal 
standard. Names were assigned to each metabolite peak based on the method of a previous 
report (21). 
 
Statistical analysis 
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The UC patients were randomly allocated to the training or validation set, and the 
HV were recruited as age- and sex-matched controls for the UC. In both the training and 
validation studies, the serum levels of metabolites were compared between the UC patients 
and HV, between UC patients in the active phase (UCa) and those in remission (UCr), and 
between the UCa/UCr and HV using the Wilcoxon’s rank sum test. Next, volcano plots and 
the stepwise method were used to select metabolite biomarker candidates for the multivariate 
analysis according to their significance and fold change values (22). The multiple logistic 
regression analysis was used to establish a diagnostic model discriminating the UC patients 
from HV as described previously (19, 23). The multicollinearity of the selected variables was 
also examined by calculating their variance inflation factors (VIF). Receiver operating 
characteristic (ROC) analysis was used to calculate area under the ROC curve (AUC), 
sensitivity, and specificity values for the model in order to evaluate its diagnostic performance, 
and the optimal cut-off value of the model was determined from its ROC curve. In the 
validation set study, the accuracy of the diagnostic model was evaluated using the cut-off 
value obtained in the training set study. Another diagnostic model for discriminating between 
the UC and CD patients was established by comparing the serum metabolite levels of the UC 
patients in the training set with those of the CD patients using Wilcoxon’s rank sum test and 
then employing the abovementioned metabolite selection method. In addition, an assessment 
model for differentiating between the UCa and UCr patients was prepared by comparing the 
serum metabolite levels of the UCr and UCa patients in the training set using Wilcoxon’s rank 
sum test and then employing the abovementioned metabolite selection method. Next, the 
correlation between the assessment model and the CAI score was evaluated using 
Spearman’s rank-correlation coefficient. 
In our study, 7 UC patients, including 4 UCa patients and 3 UCr patients, who were 
included in the abovementioned analyses were prospectively evaluated using the 
assessment model until remission or flare-up occurred, and the utility of the model as a tool 
for monitoring UC was examined. In addition, we also examined whether various factors such 
as body weight, body mass index (BMI), serum level of total protein (TP), albumin (Alb) and 
total cholesterol (T-chol), and medical treatment including medication, enteral nutrition and 
food restriction therapy influenced the alternations of metabolite biomarker candidates which 
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we selected in diagnostic and assessment models for UC. At first, the correlation between the 
metabolite alternations and the following factors; body weight, BMI and serum level of TP, Alb 
and T-chol in the sera of HV was evaluated using Spearman’s rank-correlation coefficient. 
Next, the correlation between the metabolite alternations and medical treatments; current 
dose of each salicylate; Pentasa, Asacol and sulfasalazine (SASP), azathioprine, and current 
dose and total dose within 1, 3, 6 months and 1 year of prednisolone in the sera of UCr was 
evaluated using Spearman’s rank-correlation coefficient. The correlation between the 
metabolite alternations and current total calorie of enteral nutrition; Elental and amino acid 
production in the sera of CDr was also evaluated using Spearman’s rank-correlation 
coefficient. As far infliximab, the number of CD patient’s samples was sufficient for statistical 
analysis, so we used CD patients’ data. Samples of CD patients were picked up and divided 
into two groups; administration group and non-administration group which various points such 
as age, gender ratio, BMI, medicated condition and clinical activity were matched between, 
and the alternations of metabolites were compared between two groups using the Wilcoxon 
rank sum test. Similarly, samples of UC patients were divided into two groups; food restriction 
therapy group and non-food restriction therapy group which various points such as age, 
gender ratio, BMI, medicated condition and clinical activity were matched between, and the 
alternations of metabolites were compared between two groups using Wilcoxon rank sum test. 
As far BMI and serum levels of TP and Alb in HV, we could not obtain data on all the subjects 
from reports of medical check-ups, and deficient data existed. Therefore, the 
abovementioned analysis for the correlation between the metabolite alternations and these 
data was performed using the obtained data only. The details were also demonstrated in the 
legend of Supplemental Table 10, 11. P-values of less than 0.05 were considered to indicate a 
significant difference. These analyses were carried out using the default conditions of 
JMP10.0.2 (SAS Institute Inc., Cary, NC). 
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Results 
The background information of the IBD patients and HV is summarized in Table 1 
and Supplementary table 10. In our metabolomic GC/MS-based study, which mainly targeted 
water-soluble metabolites, 114 metabolites were detected in the sera of IBD patients and HV, 
and the levels of these metabolites were compared between the UC patients and HV, 
between the UCa and UCr, and between the UCa/UCr and HV. In both the training and 
validation sets, 77 metabolites exhibited significant alterations between the UC patients and 
HV; 48 of the 77 metabolites displayed significantly decreased levels in the UC patients 
whereas 29 metabolites demonstrated significantly increased levels (Supplemental Table 1). 
Among these metabolites, the components of the TCA cycle; i.e., succinic acid, fumaric acid, 
and malic acid, and urea cycle intermediates; i.e., ornithine, citrulline, and urea, exhibited 
some of the most significant alterations, and all of these metabolites except urea displayed 
significantly decreased serum levels in the UC patients. Several amino acids such as histidine, 
isoleucine, leucine, lysine, and methionine, etc., also demonstrated significantly decreased 
levels in the UC patients. In addition, combining the results from the training and validation 
sets a total of 24 metabolites exhibited characteristic alterations between the UCa and UCr 
and/or between the UCa/UCr and HV (Fig. 1A, 1B, Supplemental Table 2), and all of these 
metabolites except pantothenate demonstrated significant correlations with the CAI in the UC 
patients (Supplemental Table 3). 
In the training set study, to establish a diagnostic model for differentiating the UC 
patients from the HV, 22 of the 114 metabolites were selected as metabolite candidates from 
volcano plots using the following criteria: the serum concentration of the metabolite had to 
differ significantly at the P<0.05 level between the UC patients and HV according to 
Wilcoxon’s rank sum test and exhibit a fold change of greater than 2.0 (Supplemental Fig. 1, 
Supplemental Table 4). Of these 22 metabolites, 4; i.e., taurine, S-benzyl-L-cysteine, maleic 
acid, and N-acetyl-L-glutamine, were selected using the stepwise method. On the basis of 
their VIF, it was confirmed that these 4 metabolites did not exhibit multicollinearity 
(Supplemental Table 5). Next, a diagnostic model consisting of the 4 metabolites was 
established using multiple logistic regression analysis as follows (Table 2): 
p=1/[1+e-{0.83-116.3(taurine)-335.3(S-benzyl-L-cysteine)+10801.1(maleic 
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acid)+2220.8(N-acetyl-L-glutamine)}]. 
 
The ROC curve obtained for this diagnostic model in the training set study is shown 
in Figure 2. The AUC of this model was 0.988, and the optimal cut-off value was 0.659. The 
model’s sensitivity and specificity values were 93.33% and 95.00%, respectively, whereas in 
the validation set study, its sensitivity and specificity values were 95.00% and 98.33%, 
respectively. Furthermore, as an additional validation set study, the metabolite data of the 39 
CD patients were subjected to this diagnostic model. When this set was used, the model was 
found to have a specificity value of 0.26% (Supplemental Fig. 2, Table 3). Therefore, although 
this diagnostic model was able to discriminate between UC and HV with high sensitivity and 
specificity, it could not distinguish between UC and CD.  
Next, a diagnostic model for discriminating between UC and CD was investigated 
using the abovementioned method. In the training set study, 9 of the 114 metabolites were 
selected as metabolite candidates from a volcano plot according to the same criteria as were 
used to develop the previous model (Supplemental Fig. 3, Supplemental Table 6). Of these, 
4 metabolites; i.e., oxalate, 3-hydroxy-butyrate, ribulose, and 1,6-anhydroglucose, were 
selected via the stepwise method, and none of them exhibited multicollinearity 
(Supplemental Table 7). The following diagnostic model was established using multiple 
logistic regression analysis (Table 4): 
p=1/[1+e-{1.36-2281.82(oxalate)-35.00(3-hydroxy-butyrate)-570.81(ribulose)+279.26(1,6-a
nhydroglucose)}]. 
 
The ROC curve obtained for this diagnostic model in the training set study is shown 
in Fig. 3. The AUC of the model was 0.965, and its optimal cut-off value was 0.653. Its 
sensitivity and specificity values were 85.00% and 97.44%, respectively. In the validation set 
study, the metabolite data of the UC patients were subjected to this diagnostic model, which 
demonstrated that it displayed 83.33% sensitivity (Table 5). In addition, we examined whether 
disease location affected the ability of the model to discriminate between UC and CD. As a 
result, it was demonstrated that the model was able to discriminate between UC and CD 
regardless of the location of the disease (Supplemental Fig. 4). 
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Finally, we investigated whether an assessment model for UC could be established. 
In the training set study, 12 of the 114 metabolites were selected as metabolite candidates 
from a volcano plot according to the same criteria as were used for the previous two models 
(Supplemental Table 8, Supplemental Fig. 5), and 2 metabolites; i.e., histidine and 
p-hydroxybenzoic acid, were selected from the 12 metabolites via the stepwise method, 
neither of which displayed multicollinearity (Supplemental Table 9). An assessment model 
consisting of these 2 metabolites was established using multiple logistic regression analysis 
as follows (Table 6): p=1/[1+e-{-1.64+380.17(histidine)-2559.38(p-hydroxybenzoic acid)}]. 
 
Based on the ROC curve obtained for this assessment model in the training set 
study (Fig. 4), its AUC was calculated as 0.967, and its optimal cut-off value was 0.421. In 
addition, its sensitivity and specificity values were 84.62% and 88.23%, respectively, whereas 
in the validation set study, its sensitivity and specificity values were 84.62% and 91.18%, 
respectively (Fig. 4, Table 7). Moreover, the values assigned to the patients by this 
assessment model exhibited a positive correlation with the CAI (Fig 5). The ability of this 
model to monitor disease activity was also evaluated. In this study, 7 UC patients were 
prospectively monitored (Fig 6). In the 4 active UC patients, the value of this model decreased 
when their CAI fell below 4 after treatment. In the 3 UC patients that were in remission, the 
model’s value increased when their condition flared-up to such an extent that their CAI were 
elevated by more than 6 points, suggesting that our UC assessment model is useful for 
monitoring disease activity. 
In addition, whether various factors such as body weight, BMI, serum levels of TP, 
Alb and T-chol, and medical treatment including medication, enteral nutrition and food 
restriction therapy influenced the alternations of selected metabolite biomarker candidates 
were examined using Spearman’s rank-correlation coefficient and Wilcoxon rank sum test 
(Supplemental Table 11, 12, 13, 15, 17, 18) The background information of the IBD patients 
who we picked up was summarized in Supplementary table 14 and 16. As a result, regarding 
10 metabolites biomarker candidates ; i.e., Oxalate, 3-Hydrobutyrate, Maleic acid, 
p-Hydroxybenzoic acid, Ribulose, Taurine, 1,6-Anhydroglucose, N-Acetyl-L-glutamate, 
Histidine, S-Benzyl-L cysteine_1, the significantly high correlation based on the following 
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statistical criteria; P value < 0.05 and rs > 0.7, or the significant alternation between 2 groups 
could not be confirmed except SASP. p-Hydroxybenzoic acid exhibited a high correlation with 
dose of SASP. 
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Discussion 
The diagnosis of IBD is dependent on comprehensive criteria based on the results 
of clinical, endoscopic, histological, and radiological examinations; however, performing all of 
these examinations is expensive and takes a long time, making it difficult to achieve an early 
diagnosis. Therefore, rapid, low cost, and non-invasive diagnostic tools for IBD are required. 
In addition, it is also difficult to discriminate UC from CD in spite of the comprehensive criteria 
that are currently used to diagnose IBD. Therefore, a diagnostic tool for discriminating 
between the different types of IBD, which would enable clinicians to select an appropriate 
treatment at an earlier point, is also required. Previously, several serological biomarkers such 
as perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA), anti-Saccharomyces 
cerevisiae antibodies (ASCA), Escherichia coli outer membrane porin (OmpC), 
Pseudomonas fluorescens-associated sequence (I2), and flagellin (CBir1) were suggested as 
diagnostic tools for IBD (9, 24-30). OmpC, I2, and CBir1 display higher prevalences among 
CD patients (24-55%) than in UC patients (2-11%) (24-30) and so might be useful for 
discriminating between UC and CD. The combination of p-ANCA and ASCA is also 
considered to be a useful serological marker for discriminating between the different types of 
IBD, and pANCA+/ASCA- displays sensitivity and specificity values of 51% and 94%, 
respectively, for detecting UC (9). Recently, Hisamatsu T et al. reported a new biomarker for 
IBD, multivariate indexes established from plasma aminograms (MIAI), which was 
constructed based on the plasma amino acid profiles of each type of IBD (31). It displayed 
superior diagnostic utility compared with the abovementioned serological markers and was 
able to discriminate UC from CD in both the active (AUC for ROC = 0.879) and remission 
phases (AUC for ROC = 0.744). Our diagnostic model based on metabolite profiling was able 
to distinguish UC from CD with high sensitivity (85.00%) and specificity (97.44%) and 
displayed a high AUC value (0.965) (Fig. 3, Table 5). 
To select appropriate treatments according to IBD status, a tool for assessing IBD 
that enables clinicians to evaluate disease activity is also required. The abovementioned 
serological biomarkers including ASCA and p-ANCA are not available for assessing disease 
activity, but fecal biomarkers, especially calprotectin, are suggested to be useful for 
monitoring UC (32-35). These biomarkers exhibit strong correlations with not only mucosal 
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activity according to endoscopy but also clinical activity based on UC symptoms in both adults 
(rs = 0.67) and children (rs = 0.68) (32,33). The MIAI has also been found to be a useful tool for 
assessing UC and is able to discriminate between UCr and UCa (AUC for ROC = 0.849). It 
also displayed a positive correlation with the CAI (rs = 0.598). Our assessment model 
displayed a superior ability to evaluate the clinical activity of UC (rs = 0.737; AUC for ROC = 
0.967) (Fig. 4, 5A, Table 7). Therefore, both our diagnostic and assessment models are useful 
clinical tools for UC. 
The IBD patients who we recruited in our study were administrated various 
medications such as salicylates, immunomoduratory agents and biological agents. The 
evaluation about influence of each medication on metabolomic profiles is required for 
improving the accuracy of our model. In addition, it is also important to evaluate whether food 
intake or food restriction therapy including enteral nutrition therapy influenced the metabolite 
alternations or not. In our study, metabolite biomarker candidates which consisted of our 
diagnostic and assessment models did not have the significantly high correlation or significant 
alternations for abovementioned factors except SASP, although the effects of tacrolimus, 
6-mercaptopurine and adalimumab could not be evaluated due to the small number of the 
patients medicated with tacrolimus, 6-mercaptopurine and adalimumab (Supplemental Table 
11, 12, 13, 14, 15, 16, 17, 18). Only the dose of SASP displayed the significantly high 
correlation with the serum level of p-Hydroxybenzoic acid. Regarding other medications, their 
sample numbers were small, although their evaluations were performed in this study, and 
therefore the more detailed evaluations about these issues may be required in the future. 
Then, in present study, the number of CD patients’ sample was smaller than that of UC, so the 
further research adding more CD patients’ samples may be also required to improve accuracy 
of our diagnostic models in the future. 
The metabolite profile of UC seems to reflect the pathogenesis of the condition in 
more detail. Our metabolomic study detected significant alterations in the levels of 77 
metabolites between HV and UC patients, and among these metabolites, 48, including 
several amino acids, TCA-related metabolites, and urea cycle-related metabolites, exhibited 
significantly decreased levels in the UC patients (Supplemental Table 1). Previously, it was 
demonstrated that stressors such as injury and infection enhanced glycolytic activity by 
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increasing cellular glucose uptake, adenosine triphosphate turnover, and adenosine 
monophosphate production, which stimulate phosphofructokinase production (36,37); 
however, a study of the global gene expression profile of the inflamed colonic tissues of UC 
patients using DNA microarrays detected the widespread downregulation of genes 
associated with protein metabolism, the urea cycle, the citric acid cycle, and oxidative 
electron transport (38). Gene set enrichment analysis (GSEA) also demonstrated the 
downregulation of ribosomal and Krebs cycle proteins in the colons of experimental colitis 
mice (39), and these reports seem to be in line with our findings. 
Our metabolomic study identified several metabolites that showed characteristic 
alterations between UCa and UCr and/or between UCa/UCr and HV (Fig. 1A, 1B, 
Supplemental Table 2) and whose levels were significantly correlated with the CAI in UC 
patients (Supplemental Table 3, Fig. 1A, 1B). IBD is regarded as the multifactorial disorder, 
and the complexity raises the necessary to take a careful consideration about IBD. However, 
these metabolites might reflect the pathogenesis of UC more closely. Of these metabolites, 
glutamine, histidine, and tryptophan have been well documented to have beneficial effects 
against inflammation. For example, the oral supplementation of an experimental colitis model 
with glutamine, histidine, or tryptophan exerted anti-inflammatory effects (15, 40, 41). In 
addition, glutamine was demonstrated to play a key role in the maintenance of gut functions; 
i.e., it was shown that glutamine has gut-protecting effects and inhibits apoptosis by 
downregulating Sp3 expression in intestinal epithelial cells (42). Glutamine also has 
anti-oxidative effects, and the glutamine supplementation of protein-depleted rats during 
inflammatory shock restored their jejunal glutathione concentrations (43). In addition, 
significantly increased levels of kynurenine and decreased levels of tryptophan were detected 
in the UC patients in the present study (Supplemental Table 2, Fig. 1A, 1B), and these results 
might reflect the pathogenesis of UC. Tryptophan is metabolized into kynurenine by 
indoleamine-2,3-dioxygenase (IDO). This leads to immunomodulatory effects (44-46), and it 
was reported that IDO is overexpressed in the intestinal lesions of UC patients (47). 
Homocysteine and citrulline also exhibited significant alterations in their levels between the 
different patient groups in our study (Fig. 1A, 1B, Supplemental Table 2), and these 
metabolites are known to be associated with IBD. Homocysteine, an intermediate product in 
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methionine metabolism, exhibited significantly increased serum levels in the UC patients (Fig. 
1A, 1B, Supplemental Table 2). Hyperhomocysteinemia displays a prevalence of 30% in UC 
patients, which is higher than that seen in healthy controls (48). Homocysteine promotes 
oxidative effects through its auto-oxidation and inhibition of glutathione peroxidase (GPx) (49) 
and was found to have thrombogenic effects on arterial endothelial cells (50), suggesting that 
hyperhomocysteinemia induces vascular events. In IBD patients, the incidence of arterial and 
venous thromboembolic events was reported to be 1-8% (51, 52), and our results suggest 
that a relationship exists between homocysteine and the risk of vascular events in UC 
patients. In addition, significant alterations in the levels of citrulline and urea, which are 
components of urea cycle-related metabolites, were also found in the UC patients in the 
present study (Fig 1A, 1B, Supplemental Table 2), and in a previous study the UC patients 
demonstrated significantly decreased plasma levels of ornithine and citrulline compared with 
the HV (31). In the present study, the serum level of arginine, which is another component of 
the urea cycle, was positively correlated with the disease activity of UC, and arginine was 
found to exert anti-inflammatory effects in DSS-treated mice (53, 54). Therefore, our results 
suggest that UC patients suffer from a disorder that affects the metabolic pathways of the 
urea cycle.  
In conclusion, using multiple logistic regression analysis we established novel and 
non-invasive serum metabolomics-based diagnostic and assessment models for UC. Our 
models demonstrated higher accuracy and/or stronger correlations with disease activity than 
previously reported biomarker candidates for UC. In addition, several metabolites displayed 
characteristic alterations in UC that varied according to disease activity. Our GC/MS 
based-metabolomic research will aid the elucidation of the pathogenesis of UC although IBD 
is one of the multifactorial disorders, and might lead to the development of a novel method for 
selecting appropriate treatments according to UC status. 
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Figure legends 
Figure 1. Metabolites that displayed altered serum levels according to the 
presence/absence of UC and disease activity  
Twenty-four metabolites showed significantly decreased (A) or increased (B) serum 
levels between the UCa and UCr, and between the UCa/UCr and HV, in both the training and 
validation sets. Data are shown as the mean ±standard deviation. P-values were calculated 
using the Wilcoxon rank sum test; *P < 0.05, **P < 0.01 ***P< 0.001. 
 
Figure 2. ROC curve for diagnostic model A 
ROC curve for the diagnostic model constructed based on the training set. Its AUC 
and cut-off values were 0.9881{95% confidence interval (95% CI): 0.9644-0.9961} and 
0.6586, respectively. 
 
Figure 3. ROC curve for diagnostic model B 
ROC curve for diagnostic model B constructed based on the training set. Its AUC 
and cut-off values were 0.9650{95% confidence interval (95% CI): 0.9214-0.9848} and 
0.6526, respectively. 
 
Figure 4. ROC curve for assessment model A 
ROC curve for assessment model A constructed based on the training set. Its AUC 
and cut-off values were 0.9667{95% confidence interval (95% CI): 0.8327-0.9777} and 
0.4214, respectively.  
 
Figure 5. Correlation between the values assigned by assessment model A and the CAI 
in the validation set 
A scatterplot with a regression line showing the correlation between the values 
assigned by assessment model A and the CAI in the validation set. {Spearman’s rank 
correlation coefficient (rs) = 0.7371 (P < 0.001), value assigned by assessment model A = 
0.067 + 0.081 × CAI score}. The values assigned by assessment model A exhibited a positive 
correlation with the CAI.  
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Figure 6. Prospective monitoring of UC with assessment model A 
In our study, 7 UC patients were prospectively monitored. The seven upper graphs 
show the alterations in the values assigned to the 7 UC patients by assessment model A, 
respectively. Among them, 4 patients (A-D) achieved remission after treatment (A), and 3 
patients (E-G) suffered flare-up (B). 
Table 1. Characteristics of the patients in the training and validation sets 
 Training set Validation set Training & validation set 
 UC HV UC  HV CD 
N (male/female) 60(21/39) 60(23/37) 60(22/38) 60(23/37) 39(26/13) 
Age a) 42.8±14.1/16-72 45.4±11.1/26-71 41.9±15.0/13-77 45.4±10.8/27-70 35.4±12.0/13-58 
Years with disease a) 8.7±7.3/0.2-23 - 7.9±6.0/0.3-21 - 9.8±8.9/0.3-32  
Disease location       
UC: P/LS/PC 7/23/30 - 7/24/29 - - 
CD: S/C/Both - - - - 10/4/25  
Disease activity a)      
CAI 3.7±3.6/0-12 - 3.6±3.8/0-15 - - 
CDAI - - - - 1202.1±98.6/0-287  
Remission/active 34/26 - 34/26 - 29/10  
Daily medication      
Salicylates 56 - 50 - 29  
Prednisolone  14 - 20 - 2  
6-Mercaptopurine 1 - 2 - 2  
Azathioprine  13 - 12 - 17  
Tacrolimus  3 - 3 - 0  
Anti-TNF-α agents 4 - 5 - 25  
Enteral nutrition - -  - 21  
a): Age, years with disease and disease activity are shown as the mean ± standard deviation together with the range. P: proctitis, LC: left-sided colitis, PC: pan-colitis, S: small bowel, C: 
colon, Both: small bowel & colon, CAI: Rachmilewitz index (a clinical activity index), CDAI: Crohn’s disease activity index. 
Table 2. Variables selected by the stepwise method 
Metabolite Coefficient Standard error P-value Lower 95% CI Upper 95% CI 
(Intercept) 0.84 2.03 0.6802 -3.29 4.94 
Taurine -116.34 37.26 0.0018 -204.86 -55.76 
S-Benzyl-L-cysteine -335.31 116.46 0.004 -607.59 -142.98 
Maleic acid 10801.09 5924.86 0.0683 162.81 24165.11 
N-Acetyl-L-glutamine 2220.85 1371.78 0.1055 241.26 5001.77 
P-values were calculated using the Wald test. 
 
 
Table 3. Diagnostic performance of our predictive model (Diagnostic model A) 
 
Training set Validation set Additional validation set 
 
UC+HV UC+HV CD 
Sensitivity (%) 93.33% 95.00% - 
Specificity (%) 95.00% 98.33% 0.26% 
Accuracy (%) 94.17% 96.67% - 
PPV 94.91% 98.28% - 
NPV 93.44% 95.16% - 
LR+ 18.67 57.00 - 
LR- 0.07 0.05 - 
PPV: positive predictive value, NPV: negative predictive value, LR+: positive likelihood ratio, LR-: negative likelihood 
ratio. The accuracy of our diagnostic model was calculated using the cut-off value obtained by ROC analysis. The cut-off value of 
the model was 0.6586. In an additional validation set study, the diagnostic model was used to assign values to 39 CD patients.  
 
 
Table 4. Variables selected by the stepwise method 
Metabolite Coefficient Standard error P-value Lower 95% CI Upper 95% CI 
(Intercept) -1.36 1.15 0.2393 -3.86 0.82 
Oxalate 2281.82 773.27 0.0032 1148.43 4446.28 
3-Hydroxybutyrate 35.00 18.89 0.0640 8.40 84.47 
Ribulose -570.81 250.43 0.0227 -1142.15 -151.30 
1,6-Anhydroglucose -279.26 260.87 0.2844 -1051.20 -1.92 
P-values were calculated using the Wald test. 
Table 5. Diagnostic performance of our predictive model (Diagnostic model B) 
 
Training set Additional validation set 
 
UC+CD UC 
Sensitivity (%) 85.00% 83.33% 
Specificity (%) 97.44 - 
Accuracy (%) 86.87% - 
PPV 98.08% - 
NPV 80.85% - 
LR+ 33.15 - 
LR- 0.15 - 
PPV: positive predictive value, NPV: negative predictive value, LR+: positive likelihood ratio, LR-: negative likelihood 
ratio. The accuracy of our diagnostic model was calculated using the cut-off value obtained from ROC analysis of the training set. 
The cut-off value was 0.6586. In an additional validation set study, diagnostic model B was used to assign values to the UC 
patients in the validation set.  
 
 
Table 6. Variables selected by the stepwise method 
Metabolite Coefficient Standard error P-value Lower 95% CI Upper 95% CI 
(Intercept) 1.64 1.12 0.1439 -0.55 4.17 
Histidine -380.17 105.29 0.0003 -638.95 -208.44 
p-Hydroxybenzoic acid 2559.38 1377.28 0.0631 865.61 6269.25 
P-values were calculated using the Wald test. 
 
 
Table 7. Diagnostic performance of our predictive model (Assessment model A) 
 
Training set Validation set 
 
UCr+UCa UCr+UCa 
Sensitivity (%) 84.62% 84.62% 
Specificity (%) 88.23% 91.18% 
Accuracy (%) 86.67% 88.33% 
PPV 84.62% 88.57% 
NPV 88.23% 95.16% 
LR+ 7.19 9.58 
LR- 0.17 0.16 
PPV: positive predictive value, NPV: negative predictive value, LR+: positive likelihood ratio, LR-: negative likelihood 
ratio. The accuracy of our diagnostic model was calculated using the cut-off value obtained from ROC analysis of the training set. 
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Figure 1-A.
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Figure 1-B.
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Supplemental Table 1. Comparison of the serum levels of all metabolites detected by GC/MS between the UC patients and HV 
 
Training set Validation set 
F.I. P-value F.I. P-value 
UC/HV UC vs. HV UC/HV UC vs. HV 
Pyruvate+oxalacetic acid 1.32  0.2670 0.99  0.0783 
Lactic acid 1.66  <.0001 1.55  <.0001 
Glycolic acid 0.94  0.0220 0.92  0.1043 
Alanine (2TMS) 1.00  0.2536 0.92  0.0135 
Hydroxybutyrate 1.50  0.0238 1.01  0.6236 
Oxalate 0.72  <.0001 0.80  0.0012 
Sarcosine 0.75  0.0003 0.63  <.0001 
2-Aminoisobutyrate 0.93  0.1619 0.85  0.0029 
3-Hydroxybutyrate 4.18  0.3199 1.75  0.2164 
2-Aminobutyric acid 0.87  0.0043 0.73  <.0001 
Ketoisoleucine_1 1.15  0.5514 0.93  0.0288 
Malonic acid 2.09  <.0001 1.89  <.0001 
3-Hydroxyisovaleric acid 1.42  0.0033 1.08  0.2223 
Valine (2TMS) 0.74  <.0001 0.71  <.0001 
Urea 2.44  <.0001 2.37  <.0001 
Oxamic acid 0.84  0.6162 2.96  0.6015 
2-Aminoethanol 0.75  <.0001 0.72  <.0001 
n-Caprylic acid 0.89  <.0001 0.74  <.0001 
Phosphate 0.75  <.0001 0.69  <.0001 
Glycerol 2.21  0.7910 2.14  0.0621 
Ethylmalonic acid 1.95  <.0001 1.81  <.0001 
Isoleucine 0.82  0.0004 0.71  <.0001 
Threonine (2TMS) 0.87  0.0079 0.75  <.0001 
Proline 0.81  0.0022 0.79  0.001 
Maleic acid 2.02  <.0001 2.07  <.0001 
Glycine (3TMS) 0.98  0.1957 0.94  0.357 
Succinic acid (or aldehyde) 0.77  <.0001 0.71  <.0001 
Catechol 1.90  <.0001 1.72  <.0001 
Glyceric acid 0.86  0.0066 0.85  0.0027 
Uracil 1.94  <.0001 1.70  <.0001 
Fumaric acid 0.65  <.0001 0.60  <.0001 
Serine (3TMS) 0.61  <.0001 0.62  <.0001 
Nonanoic acid (C9) 0.47  <.0001 0.48  <.0001 
4-Methylbenzoic acid 1.56  <.0001 1.22  <.0001 
Glutaric acid 0.86  0.0783 0.93  0.4204 
Maleamic acid 1.18  0.0003 0.99  0.0360 
Prolinamide 2.07  <.0001 1.84  <.0001 
Homoserine 0.86  0.0024 0.85  0.0017 
Malic acid 0.77  <.0001 0.68  <.0001 
Threitol 0.91  0.2366 1.00  0.7708 
meso-Erythritol 1.01  0.3199 3.20  0.0537 
Adipic acid 1.10  0.0284 1.33  0.0004 
Acetylsalicylic acid 6.43  <.0001 0.63  <.0001 
Aspartic acid 0.82  <.0001 0.81  <.0001 
Methionine 0.82  <.0001 0.73  <.0001 
trans-4-Hydroxy-L-proline 0.67  <.0001 0.59  <.0001 
4-Aminobutyric acid 2.10  <.0001 1.45  0.0013 
Pyrogallol 0.49  0.6273 0.68  0.2647 
Creatinine 0.80  0.0015 0.78  0.0016 
Acetoacetic acid 0.25  <.0001 0.26  <.0001 
β-Glutamic acid 2.11  <.0001 1.96  <.0001 
Glutamic acid 0.79  <.0001 0.70  <.0001 
Phenylalanine 0.90  0.0002 0.79  <.0001 
5-Aminovaleric acid 0.88  0.1699 0.72  0.0023 
p-Hydroxybenzoic acid 2.07  <.0001 1.84  <.0001 
Xylose_2 2.12  0.0035 2.46  0.1651 
threo-β-Hydroxyaspartic acid 1.25  <.0001 1.40  <.0001 
Lyxose_2 1.01  0.4055 0.99  0.0017 
Arabinose 1.00  0.5067 1.04  0.5237 
Lauric acid 0.91  0.0161 0.77  <.0001 
N-Acetyl-L-aspartic acid_2 1.81  <.0001 1.92  <.0001 
Homocysteine_1 1.92  <.0001 1.70  <.0001 
Ribose 1.21  0.7548 1.44  0.0925 
Ribulose 0.87  0.1100 1.00  0.2471 
Asparagine 0.60  <.0001 0.56  <.0001 
Taurine 0.18  <.0001 0.25  <.0001 
Cysteine sulfonic acid 0.96  0.6919 0.95  0.3879 
Xylitol 0.97  0.2031 0.94  0.0245 
1,6-Anhydroglucose 1.45  0.0010 1.93  <.0001 
Arabitol 0.76  0.0666 0.93  0.0765 
Ribitol 1.25  0.3123 0.96  0.4388 
Aconitate 1.10  0.9812 0.92  0.0013 
N-Acetyl-L-glutamate_1 3.32  <.0001 3.34  0.0003 
Glutamine 0.60  <.0001 0.54  <.0001 
4-Hydroxymandelate 0.55  <.0001 0.43  <.0001 
Dihydroorotate 1.92  <.0001 1.73  <.0001 
O-Phosphoethanolamine 0.35  <.0001 0.34  <.0001 
Theanine_2 0.58  0.0020 0.63  0.0017 
Glycyl-glycine_1 0.62  <.0001 0.71  <.0001 
Citric acid + isocitric acid 0.70  <.0001 0.70  <.0001 
Ornithine 0.87  0.0065 0.84  0.0002 
Hypoxanthine 0.84  0.0027 0.93  0.081 
Citrulline 0.63  <.0001 0.58  <.0001 
1,5-Anhydro-D-glucitol 0.59  <.0001 0.72  0.001 
Tagatose_2 (or psicose_2) 0.74  <.0001 0.59  <.0001 
Fructose_1 1.07  0.9561 1.13  0.1124 
2-Dehydro-D-gluconate_1 1.20  <.0001 1.28  <.0001 
Glucose_1 1.89  <.0001 1.82  <.0001 
Sebacic acid 1.46  0.0292 1.81  0.2580 
Galactose_2 2.05  <.0001 1.00  0.0055 
Mannitol 1.08  0.6498 2.89  0.0103 
Lysine (4TMS) 0.96  0.0053 0.85  0.0008 
Galactosamine_1 1.03  0.0369 0.93  0.0394 
Histidine 0.37  <.0001 0.37  <.0001 
Glucuronate_1 0.77  <.0001 0.69  <.0001 
5-Keto-D-gluconate_2 0.86  0.7036 0.89  0.4673 
Galacturonic acid_1 1.98  <.0001 2.10  <.0001 
Tyrosine 0.82  <.0001 0.68  <.0001 
Pantothenate 1.42  <.0001 1.32  <.0001 
N-α-Acetyl-L-ornithine_2 2.05  <.0001 1.99  <.0001 
Glucarate 0.66  <.0001 0.66  <.0001 
S-Benzyl-L-cysteine_1 0.20  <.0001 0.23  <.0001 
Xanthine 0.82  0.0031 0.80  0.0001 
Palmitoleate 0.75  0.0003 0.44  <.0001 
Inositol 0.81  0.0001 0.78  <.0001 
Dopa 2.00  <.0001 1.90  <.0001 
Uric acid 0.63  <.0001 0.59  <.0001 
N-α-Acetyl-L-lysine_2 5.89  0.0493 5.89  0.8194 
Heptadecanoate 0.58  0.0004 0.63  0.0525 
Kynurenine 2.46  <.0001 2.01  <.0001 
Cystathionine 0.71  0.5305 0.72  0.7829 
Cystamine 2.12  <.0001 3.41  <.0001 
Tryptophan 0.65  <.0001 0.58  <.0001 
Elaidic acid 0.81  0.9352 0.55  0.0355 
Homocysteine 2.03  <.0001 2.11  <.0001 
Values are shown as fold induction (F.I.) values, which were obtained by comparing the peak intensity values of the UC 
patients with those of the HV. The peak intensity values for each quantified ion have been normalized to that of 2-isopropylmalic acid as 
an internal standard. P-values were calculated using the Wilcoxon rank sum test. 
 
Supplemental Table 2. Comparison of the serum levels of all metabolites detected by GC/MS among UCa patients, UCr patients, and HV  
 Training set Validation set 
F.I. P-value F.I. P-value F.I. P-value F.I. P-value F.I. P-value F.I. P-value 
UCr/HV UCr vs. HV UCa/HV UCa vs. HV UCa/UCr UCa vs. 
UCr 
UCr/HV UCr vs. HV UCa/HV UCa vs. HV UCa/UCr UCa vs. 
UCr 
Pyruvate+oxalacetic acid 0.97  0.4064 1.76  0.0028 1.81  0.0043 0.78  0.0004 1.28  0.2859 1.64  0.0136 
Lactic acid 1.40  <.0001 2.00  <.0001 1.43  <.0001 1.37  <.0001 1.77  <.0001 1.29  0.0002 
Glycolic acid 0.97  0.5011 0.90  0.001 0.93  0.0633 1.02  0.8103 0.78  0.0088 0.76  0.0212 
Alanine (2TMS) 1.01  0.7086 0.99  0.111 0.98  0.4973 0.92  0.0201 0.93  0.1008 1.01  0.994 
Hydroxybutyrate 1.04  0.3311 2.11  <.0001 2.03  <.0001 0.82  0.0242 1.26  0.0703 1.53  0.0028 
Oxalate 0.93  0.0544 0.44  <.0001 0.48  <.0001 0.97  0.2332 0.57  <.0001 0.58  0.0002 
Sarcosine 0.90  0.2211 0.55  <.0001 0.61  0.0011 0.70  0.0016 0.52  <.0001 0.74  0.0432 
2-Aminoisobutyrate 0.85  0.0021 1.02  0.2417 1.19  0.0071 0.77  <.0001 0.96  0.7456 1.25  0.0039 
3-Hydroxybutyrate 2.33  0.1578 6.61  0.0005 2.84  0.0008 0.81  0.0036 2.97  0.206 3.67  0.0092 
2-Aminobutyric acid 0.77  <.0001 1.01  0.7173 1.32  0.0119 0.69  <.0001 0.78  0.0042 1.13  0.1723 
Ketoisoleucine_1 0.90  0.0227 1.47  0.0001 1.63  0.0002 0.75  <.0001 1.16  0.1361 1.55  <.0001 
Malonic acid 1.84  <.0001 2.42  <.0001 1.32  0.0013 1.58  <.0001 2.29  <.0001 1.45  0.0002 
3-Hydroxyisovaleric acid 0.91  0.0885 2.10  0.0012 2.32  0.0059 0.74  0.6623 1.53  0.097 2.06  0.13 
Valine (2TMS) 0.76  <.0001 0.71  <.0001 0.94  0.6599 0.74  <.0001 0.66  <.0001 0.90  0.1055 
Urea 2.11  <.0001 2.87  <.0001 1.36  0.0013 2.13  <.0001 2.68  <.0001 1.26  0.0003 
Oxamic acid 0.95  0.7262 0.71  0.6349 0.75  0.2729 0.57  0.3311 6.09  0.8251 10.72  0.5261 
2-Aminoethanol 0.65  <.0001 0.89  0.0499 1.38  0.0002 0.63  <.0001 0.83  0.0075 1.32  0.0021 
n-Caprylic acid 1.01  0.0139 0.75  <.0001 0.74  0.0204 0.70  <.0001 0.80  0.0004 1.14  0.1586 
Phosphate 0.75  <.0001 0.76  <.0001 1.01  0.6278 0.69  <.0001 0.69  <.0001 1.00  0.7711 
Glycerol 0.76  0.0002 4.12  <.0001 5.43  <.0001 0.64  <.0001 4.10  0.0249 6.42  0.0004 
Ethylmalonic acid 1.70  <.0001 2.29  <.0001 1.35  0.0005 1.61  <.0001 2.07  <.0001 1.29  0.002 
Isoleucine 0.84  0.0022 0.80  0.0065 0.95  0.4248 0.73  <.0001 0.67  <.0001 0.92  0.4423 
Threonine (2TMS) 0.83  0.0015 0.93  0.3351 1.12  0.0348 0.74  <.0001 0.76  0.0004 1.02  0.6173 
Proline 0.86  0.065 0.75  0.001 0.88  0.1226 0.85  0.0524 0.72  0.0004 0.85  0.022 
Maleic acid 1.78  <.0001 2.32  <.0001 1.31  0.0018 1.87  <.0001 2.33  <.0001 1.25  0.0289 
Glycine (3TMS) 0.90  0.002 1.09  0.1713 1.21  0.0092 0.94  0.1928 0.94  0.9288 1.00  0.5861 
Succinic acid (or aldehyde) 0.82  0.0003 0.70  <.0001 0.86  0.0323 0.72  <.0001 0.70  <.0001 0.97  0.0933 
Catechol 1.84  <.0001 1.98  <.0001 1.08  0.15 1.68  <.0001 1.76  <.0001 1.05  0.0388 
Glyceric acid 0.94  0.2181 0.74  0.0007 0.79  0.0229 0.94  0.2363 0.72  <.0001 0.76  0.0047 
Uracil 1.69  <.0001 2.28  <.0001 1.35  0.0035 1.39  <.0001 2.10  <.0001 1.51  <.0001 
Fumaric acid 0.78  <.0001 0.49  <.0001 0.63  <.0001 0.63  <.0001 0.56  <.0001 0.89  0.1918 
Serine (3TMS) 0.60  <.0001 0.62  <.0001 1.04  0.9584 0.67  <.0001 0.56  <.0001 0.84  0.0822 
Nonanoic acid (C9) 0.51  <.0001 0.42  <.0001 0.82  0.0323 0.50  <.0001 0.45  <.0001 0.89  0.0962 
4-Methylbenzoic acid 1.55  <.0001 1.58  <.0001 1.02  0.2075 1.27  0.0043 1.16  0.0001 0.92  0.2795 
Glutaric acid 0.80  0.0252 0.93  0.6349 1.15  0.1458 0.78  0.0616 1.13  0.4324 1.44  0.0007 
Maleamic acid 1.07  0.0247 1.33  0.0002 1.24  0.0047 0.95  0.151 1.03  0.0418 1.09  0.1377 
Prolinamide 1.79  <.0001 2.44  <.0001 1.37  0.0007 1.55  <.0001 2.23  <.0001 1.43  <.0001 
Homoserine 0.81  0.0006 0.94  0.1803 1.16  0.1121 0.82  0.0016 0.87  0.0633 1.06  0.1631 
Malic acid 0.86  0.001 0.65  <.0001 0.76  0.0654 0.67  <.0001 0.69  <.0001 1.03  0.7371 
Threitol 1.05  0.5845 0.72  0.0055 0.69  0.0065 1.03  1 0.95  0.6018 0.93  0.5261 
meso-Erythritol 1.18  0.9969 0.78  0.0732 0.66  0.1631 2.23  0.2301 4.48  0.0437 2.01  0.4973 
Adipic acid 0.99  0.4109 1.23  0.0033 1.25  0.013 0.99  0.0487 1.78  <.0001 1.79  0.0012 
Acetylsalicylic acid 9.97  <.0001 1.80  <.0001 0.18  0.1543 0.49  0.0031 0.81  <.0001 1.66  0.0002 
Aspartic acid 0.88  <.0001 0.75  <.0001 0.86  0.0011 0.85  <.0001 0.75  <.0001 0.89  0.0025 
Methionine 0.74  <.0001 0.93  0.011 1.25  0.0796 0.67  <.0001 0.80  0.0019 1.19  0.1226 
trans-4-Hydroxy-L-proline 0.67  <.0001 0.67  <.0001 1.00  0.1377 0.70  0.0001 0.45  <.0001 0.64  0.0009 
4-Aminobutyric acid 1.77  0.0192 2.52  <.0001 1.43  0.0001 1.05  0.429 1.98  <.0001 1.88  <.0001 
Pyrogallol 0.55  0.8164 0.40  0.5567 0.72  1 0.68  0.376 0.69  0.3495 1.00  0.8287 
Creatinine 0.87  0.1444 0.70  <.0001 0.81  0.0534 0.83  0.0544 0.72  0.0008 0.88  0.314 
Acetoacetic acid 0.24  <.0001 0.27  <.0001 1.11  0.119 0.25  <.0001 0.27  <.0001 1.09  0.0962 
β-Glutamic acid 1.81  <.0001 2.51  <.0001 1.39  0.0002 1.79  <.0001 2.18  <.0001 1.22  0.0173 
Glutamic acid 0.62  <.0001 1.01  0.1598 1.61  0.0188 0.65  <.0001 0.76  0.0155 1.18  0.2241 
Phenylalanine 0.83  <.0001 1.00  0.0933 1.22  0.6278 0.79  <.0001 0.80  <.0001 1.02  0.9109 
5-Aminovaleric acid 0.73  0.0117 1.07  0.5823 1.47  0.0026 0.59  0.0002 0.89  0.3212 1.52  0.0004 
p-Hydroxybenzoic acid 0.92  0.0013 3.58  <.0001 3.90  0.0002 1.22  <.0001 2.64  <.0001 2.17  0.0022 
Xylose_2 1.91  0.2793 2.40  <.0001 1.25  0.0085 1.58  0.7381 3.62  0.0373 2.29  0.2075 
threo-β-Hydroxyaspartic acid 1.18  0.0133 1.34  <.0001 1.14  0.0962 1.10  0.076 1.79  <.0001 1.63  0.0016 
Lyxose_2 0.95  0.1128 1.09  0.6894 1.15  0.2416 0.83  <.0001 1.19  0.8105 1.43  0.0034 
Arabinose 0.87  0.0058 1.17  0.0356 1.35  0.0059 0.91  0.0247 1.21  0.1242 1.33  0.0101 
Lauric acid 0.95  0.2066 0.85  0.0052 0.90  0.2075 0.75  <.0001 0.79  0.0001 1.06  0.7597 
N-Acetyl-L-aspartic acid_2 1.56  <.0001 2.15  <.0001 1.38  0.0016 1.70  <.0001 2.22  <.0001 1.31  0.0008 
Homocysteine_1 1.70  <.0001 2.20  <.0001 1.29  0.0031 1.44  <.0001 2.04  <.0001 1.41  0.0005 
Ribose 0.95  0.6284 1.55  0.2533 1.62  0.4603 1.12  0.3593 1.85  0.0557 1.65  0.336 
Ribulose 0.82  0.0584 0.95  0.5504 1.16  0.5457 0.83  0.0339 1.22  0.6484 1.46  0.2356 
Asparagine 0.70  <.0001 0.46  <.0001 0.67  0.0002 0.66  <.0001 0.43  <.0001 0.65  <.0001 
Taurine 0.19  <.0001 0.17  <.0001 0.94  0.2021 0.25  <.0001 0.26  <.0001 1.01  0.0676 
Cysteine sulfonic acid 0.96  0.7086 0.97  0.796 1.02  0.6707 0.90  0.1849 1.03  0.9737 1.15  0.1024 
Xylitol 1.06  0.376 0.84  0.0008 0.79  0.0016 0.95  0.1146 0.92  0.0324 0.97  0.9584 
1,6-Anhydroglucose 1.65  0.0043 1.19  0.0122 0.72  0.8873 1.68  0.0003 2.25  0.0001 1.34  0.2729 
Arabitol 1.03  0.249 0.40  <.0001 0.39  <.0001 1.00  0.9655 0.83  0.0018 0.83  0.0141 
Ribitol 1.49  0.0389 0.94  0.5134 0.63  0.1458 1.07  0.9718 0.82  0.1803 0.77  0.1969 
Aconitate 1.23  0.0976 0.92  0.0427 0.75  0.0037 0.98  0.0945 0.84  0.0002 0.86  0.0403 
N-Acetyl-L-glutamate_1 1.93  0.0162 5.14  <.0001 2.66  0.0001 1.39  0.343 5.89  <.0001 4.25  <.0001 
Glutamine 0.70  <.0001 0.48  <.0001 0.68  0.0014 0.62  <.0001 0.45  <.0001 0.73  0.0004 
4-Hydroxymandelate 0.60  0.0013 0.47  0.0015 0.78  0.6491 0.42  <.0001 0.45  <.0001 1.07  0.0181 
Dihydroorotate 1.70  <.0001 2.21  <.0001 1.30  0.0125 1.44  <.0001 2.12  <.0001 1.48  <.0001 
O-Phosphoethanolamine 0.33  <.0001 0.37  <.0001 1.09  0.9109 0.32  <.0001 0.36  <.0001 1.12  0.3748 
Theanine_2 0.54  0.0037 0.64  0.0381 1.19  0.0417 0.54  0.0012 0.75  0.0795 1.39  0.0025 
Glycyl-glycine_1 0.69  <.0001 0.53  <.0001 0.77  0.0022 0.87  0.124 0.50  <.0001 0.57  <.0001 
Citric acid + isocitric acid 0.77  0.0001 0.60  <.0001 0.78  0.0229 0.72  <.0001 0.68  0.0001 0.95  0.1676 
Ornithine 0.69  <.0001 1.10  0.5567 1.60  <.0001 0.67  <.0001 1.07  0.9064 1.59  0.0017 
Hypoxanthine 0.78  0.0008 0.91  0.1655 1.17  0.314 0.91  0.0813 0.97  0.2988 1.07  0.9109 
Citrulline 0.78  0.0002 0.45  <.0001 0.58  <.0001 0.65  <.0001 0.49  <.0001 0.76  0.0007 
1,5-Anhydro-D-glucitol 0.72  0.0002 0.41  <.0001 0.58  0.0092 0.84  0.0444 0.56  0.0005 0.66  0.0229 
Tagatose_2 (or psicose_2) 0.76  <.0001 0.71  0.0002 0.93  0.1155 0.61  <.0001 0.56  <.0001 0.91  0.0311 
Fructose_1 1.38  0.0232 0.68  0.0091 0.49  0.001 1.54  <.0001 0.58  0.0027 0.38  <.0001 
2-Dehydro-D-gluconate_1 0.72  <.0001 1.84  <.0001 2.57  0.0023 0.66  <.0001 2.09  <.0001 3.19  0.0041 
Glucose_1 1.80  <.0001 2.01  <.0001 1.11  0.1121 1.70  <.0001 1.99  <.0001 1.17  0.0009 
Sebacic acid 0.62  0.0087 2.56  0.4435 4.12  0.2664 0.62  0.0205 3.36  0.4604 5.45  0.0011 
Galactose_2 1.45  <.0001 2.83  0.0007 1.95  0.2129 0.96  0.0496 1.05  0.0088 1.09  0.8991 
Mannitol 1.02  0.402 1.16  0.8545 1.15  0.4694 3.07  0.1673 2.66  0.0033 0.87  0.3285 
Lysine (4TMS) 0.74  <.0001 1.23  0.3032 1.66  0.0002 0.68  <.0001 1.08  0.2306 1.59  0.0014 
Galactosamine_1 1.01  0.5162 1.06  0.0031 1.05  0.0167 0.96  0.402 0.90  0.0073 0.94  0.0612 
Histidine 0.54  <.0001 0.16  <.0001 0.31  <.0001 0.54  <.0001 0.16  <.0001 0.30  <.0001 
Glucuronate_1 0.90  0.0001 0.61  <.0001 0.68  0.3435 0.68  <.0001 0.70  0.0003 1.03  0.8638 
5-Keto-D-gluconate_2 0.79  0.1578 0.96  0.3166 1.21  0.0267 0.70  0.0058 1.13  0.0467 1.62  <.0001 
Galacturonic acid_1 1.75  <.0001 2.29  <.0001 1.31  0.013 1.85  <.0001 2.43  <.0001 1.31  0.0023 
Tyrosine 0.88  0.0024 0.73  <.0001 0.83  0.1088 0.69  <.0001 0.67  <.0001 0.97  0.3993 
Pantothenate 1.32  <.0001 1.55  <.0001 1.17  0.0361 1.16  0.0346 1.53  <.0001 1.32  0.0011 
N-α-Acetyl-L-ornithine_2 1.75  <.0001 2.43  <.0001 1.38  0.0002 1.81  <.0001 2.24  <.0001 1.24  0.0101 
Glucarate 0.78  0.0002 0.50  <.0001 0.65  <.0001 0.72  <.0001 0.59  <.0001 0.81  0.0257 
S-Benzyl-L-cysteine_1 0.10  <.0001 0.33  <.0001 3.15  0.5759 0.09  <.0001 0.41  0.0002 4.33  0.0654 
Xanthine 0.84  0.0169 0.79  0.0147 0.94  0.6173 0.84  0.0042 0.76  0.0005 0.91  0.3512 
Palmitoleate 0.65  0.0005 0.87  0.02 1.33  0.1458 0.43  <.0001 0.44  <.0001 1.02  0.5068 
Inositol 0.79  <.0001 0.82  0.0488 1.03  0.5657 0.70  <.0001 0.88  0.0125 1.25  0.0962 
Dopa 1.75  <.0001 2.32  <.0001 1.33  0.002 1.70  <.0001 2.16  <.0001 1.27  0.0119 
Uric acid 0.72  <.0001 0.52  <.0001 0.73  0.0311 0.64  <.0001 0.53  <.0001 0.83  0.1586 
N-α-Acetyl-L-lysine_2 8.40  0.1849 2.60  0.0533 0.31  0.9465 8.27  0.6738 2.78  0.3592 0.34  0.3512 
Heptadecanoate 0.57  0.0033 0.59  0.0052 1.02  0.336 0.60  0.0505 0.67  0.2572 1.13  0.011 
Kynurenine 1.87  <.0001 3.24  <.0001 1.74  <.0001 1.51  <.0001 2.68  <.0001 1.78  <.0001 
Cystathionine 0.60  0.978 0.86  0.2775 1.44  0.0278 0.56  0.1279 0.93  0.0205 1.66  <.0001 
Cystamine 1.26  0.0012 3.24  <.0001 2.58  0.0167 1.16  0.0102 6.36  <.0001 5.47  0.0001 
Tryptophan 0.71  <.0001 0.57  <.0001 0.80  0.0047 0.69  0.0003 0.42  <.0001 0.61  0.0003 
Elaidic acid 0.80  0.9092 0.82  0.9962 1.03  0.0612 0.49  0.0308 0.64  0.238 1.31  0.0035 
Homocysteine 1.79  <.0001 2.34  <.0001 1.31  0.013 1.86  <.0001 2.43  <.0001 1.31  0.0023 
Disease activity was assessed with the Rachmilewitz index; i.e., a clinical activity index (CAI). Active disease was defined as a CAI of ≥ 6 for UC (UC in the active phase: UCa). Remission was defined as 
a CAI of < 6 for UC (UC in remission: UCr).Values are represented as fold induction (F.I.) values of peak intensity values in the comparisons among the UCr, UCa, and HV. The peak intensity values for each 
quantified ion were normalized to that of 2-isopropylmalic acid as an internal standard. P-values were calculated using the Wilcoxon rank sum test. 
 
Supplemental Table 3. Spearman’s rank correlation coefficients (rs) for the relationships between the CAI and the 24 metabolites that 
exhibited significant alterations according to disease activity or the presence/absence of disease  
 
Training set  Validation set  
 
rs P-value  rs P-value  
Aspartic acid  -0.2993 0.0202 -0.3817 0.0026 
Asparagine  -0.3969 0.0017 -0.641 <.0001  
Glutamine  -0.3329 0.0094 -0.5559 <.0001  
Citrulline  -0.5551 <.0001  -0.4361 0.0005 
1,5-Anhydro-D-glucitol  -0.3523 0.0058 -0.3474 0.0065 
Histidine  -0.5249 <.0001  -0.7436 <.0001  
Glucarate  -0.4733 0.0001 -0.266 0.04 
Tryptophan  -0.4472 0.0003 -0.5568 <.0001  
Lactic acid  0.5978 <.0001  0.5281 <.0001  
Malonic acid  0.3538 0.0056 0.5087 <.0001  
Urea  0.3201 0.0127 0.5125 <.0001  
Ethylmalonic acid  0.3618 0.0045 0.5348 <.0001  
Maleic acid  0.3469 0.0066 0.278 0.0315 
Uracil  0.3214 0.0123 0.6098 <.0001  
Prolinamide  0.3831 0.0025 0.6258 <.0001  
β-Glutamic acid  0.4199 0.0008 0.4164 0.0009 
N-Acetyl-L-aspartic acid_2  0.3143 0.0145 0.5373 <.0001  
Dihydroorotate  0.304 0.0182 0.6999 <.0001  
Galacturonic acid_1  0.2793 0.0307 0.3949 0.0018 
Pantothenate  0.2344 NS  0.4724 0.0001 
N-α-Acetyl-L-ornithine_2  0.422 0.0008 0.4213 0.0008 
Dopa  0.3705 0.0036 0.3323 0.0095 
Kynurenine  0.4229 0.0008 0.583 <.0001  
Homocysteine  0.2793 0.0307 0.3949 0.0018 
NS: not significant. Spearman’s rank correlation coefficients (rs) were calculated for the relationships between the CAI and the 24 
metabolites that exhibited significant alterations according to disease activity or the presence/absence of disease. 
 
Supplemental Table 4. Twenty-two metabolites selected from a volcano plot of UC versus HV  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The X and Y axes of the Volcano plot showed Log2 fold induction (F.I.) values and –log10 p-values, respectively. The above 22 
metabolites met the following criteria: fold induction > 2.0; i.e., |log2 of F.I.| > 1, and p-value > 0.05; i.e., –log10 of p value > 1.301029996. 
P-values were calculated using Wilcoxon rank sum test. 
 
 log2(F.I.) (X axis) -log10(P-value) (Y axis) 
Malonic acid 1.062041005 >12 
Urea 1.284873133 >12 
Maleic acid 1.010995484 >12 
Nonanoic acid (C9) -1.082985088 >12 
Prolinamide 1.050293668 >12 
Acetylsalicylic acid 2.684350319 >12 
4-Aminobutyric acid 1.067392629 5.287906147 
Acetoacetic acid -1.997662002 7.070581074 
β-Glutamic acid 1.079983692 >12 
p-Hydroxybenzoic acid 1.052647743 6.382789905 
Xylose_2 1.086430825 2.457102093 
Taurine -2.466213592 >12 
N-Acetyl-L-glutamate_1 1.732777541 6.240105626 
O-Phosphoethanolamine -1.524368073 8.585026652 
Galactose_2 1.034690833 5.462999913 
Histidine -1.415784243 >12 
N-α-Acetyl-L-ornithine_2 1.033225873 >12 
S-Benzyl-L-cysteine_1 -2.307528402 7.913640169 
N-α-Acetyl-L-lysine_2 2.557824764 1.306773807 
Kynurenine 1.300074675 >12 
Cystamine 1.082590369 6.275642196 
Homocysteine 1.021748676 >12 
Supplemental Table 5. VIF of the variables in diagnostic model A  
Variable VIF 
Taurine 1.77 
S-Benzyl-L-cysteine 1.12 
N-Acetyl-L-glutamine 1.32 
Maleic acid 1.97 
The 4 metabolites; i.e., taurine, S-benzyl-L-cysteine, maleic acid, and N-acetyl-L-glutamine that made up diagnostic model A, 
which was able to discriminate the UC patients from HV as follows: 
p=1/[1+e-{0.83-116.3(Taurine)-335.3(s-Benzyl-L-cysteine)+10801.1(Maleic acid)+2220.8(n-Acetyl-L-glutamine)}]. 
 
 
Supplemental Table 6. Nine metabolites selected from a volcano plot of UC versus CD  
 log2(fold change) log10(p-value) 
Oxalate -1.659772104 9.000000000 
3-Hydroxybutyrate -3.014294754 3.317757241 
Acetylsalicylic acid -1.448047145 3.248290357 
p-Hydroxybenzoic acid 1.294445194 7.183758700 
Ribulose 1.338250558 7.552841969 
1,6-Anhydroglucose 2.617149363 3.900771841 
N-Acetyl-L-glutamate_1 1.229194931 8.431798276 
2-Dehydro-D-gluconate_1 1.018103046 6.181906131 
Histidine -1.910157875 4.937997461 
The X and Y axes of the Volcano plot showed Log2 fold induction (F.I.) values and –log10 p-values, respectively. The above 9 
metabolites met the following criteria: fold induction > 2.0; i.e., |log2 of F.I.| > 1, and p-value > 0.05; i.e., –log10 of p value > 1.301029996. 
P-values were calculated using the Wilcoxon rank sum test. 
 
 
Supplemental Table 7. VIF of the variables in diagnostic model B  
Variable VIF 
Oxalate 1.21 
3-Hydroxybutyrate 1.06 
Ribulose 1.37 
1,6-Anhydroglucose 1.15 
The 4 metabolites; i.e., oxalate, 3-hydroxy-butyrate, ribulose and 1,6-anhydroglucose, that made up diagnostic model B, which 
was able to discriminate between the UC patients and CD patients as follows: 
p=1/[1+e-{1.36-2281.82(Oxalate)-35.00(3-Hydroxybutyrate)-570.81(Ribulose)+279.26(1,6-Anhydroglucose)}]. 
 
 
Supplemental Table 8. Twelve metabolites selected from a volcano plot of UCr versus UCa  
 log2(F.I.) log10(P-value) 
Hydroxybutyrate 1.019579642 5.694326254 
Oxalate -1.058554613 6.019451261 
3-Hydroxybutyrate 1.507059903 3.114396706 
3-Hydroxyisovaleric acid 1.211874346 2.227839107 
Glycerol 2.440845122 6.873219423 
p-Hydroxybenzoic acid 1.963311328 3.781411984 
Arabitol -1.35185713 4.952047928 
N-Acetyl-L-glutamate_1 1.409605033 3.991857356 
Fructose_1 -1.02785869 2.998161403 
2-Dehydro-D-gluconate_1 1.359687026 2.641410567 
Histidine -1.701649185 5.378532901 
Cystamine 1.367684057 1.778504581 
The X and Y axes of the Volcano plot showed Log2 fold induction (F.I.) values and –log10 p-values, respectively. The above 12 
metabolites met the following criteria: fold induction > 2.0; i.e., |log2 of F.I.| > 1, and p-value > 0.05; i.e., –log10 of p value > 1.301029996. 
P-values were calculated using the Wilcoxon rank sum test. 
 
 
Supplemental Table 9. VIF of the variables in assessment model A  
Variable VIF 
Histidine 1.01 
p-Hydroxybenzoic acid 1.01 
The 2 metabolites; i.e., histidine and p-hydroxybenzoic acid, that made up assessment model A, which was found to be useful for 
prospectively monitoring UC as follows: p=1/[1+e-{-1.64+380.17(histidine)-2559.38(p-hydroxybenzoic acid
Supplemental Table 10. Additional information of the patients in the training and validation sets 
  Training set   Validation set   Training & validation set 
  UC HV UC  HV CD 
Body weight (kg) a) 54.1±9.1/36.8-76.0 58.2±11.0/40.6-84.9 b) 56.8±11.0/32.9-90.0 57.4±10.7/41.9-86.5 b) 57.2±9.8/36.0-73.0 
BMI a) 20.6±2.8/14.9-27.6 21.5±2.6/17.3-28.3 21.3±3.3/14.7-34.7 21.9±2.7/17.3-27.8 20.7±3.0/14.1-26.7 
Daily medication      
Salicylates (N) 56 0 50 0 29 
Pentasa (N) 30 - 30 - 29 
dose / dose range (mg/day) a) 1583±1709/0-4000 - 1544±1677/0-4000 - 2130±1311/0-3000 
Asacol (N) 22 - 16 - 0 
dose / dose range (mg/day) a) 1260±1688/0-3600 - 980±1585/0-3600 - - 
SASP (N) 4 - 4 - 0 
dose / dose range (mg/day) a) 183±747/0-4000 - 233±958/0-4500 - - 
Prednisolone (N) 14 0 20 0 2 
Total dose for 1 year (mg) a) 749±1197/0-5200 - 568±1004/0-5087 - 62.7±279.4 
Total dose for 6 months (mg) a) 436±828/0-3520 - 345±654/0-3057 - 27.6±136.6 
Total dose for 3 months (mg) a) 234±612/0-3520 - 183±391/0-1960 - 12.9±68.2 
Total dose for 1 month (mg) a) 135±431/0-2960 - 72.1±195/0-1150 - 4.3±22.7 
Current dose (mg/day) a) 5.8±15.0/0-80 - 3.3±11.7/0-80 - 0.2±0.8 
6-mercaptopurine (N) 1 0 2 0 2 
dose / dose range (mg/day) a) 0.5±1.5/0-30 - 1.3±7.5 - 1.7±7.5/0-40 
dosing period (month) a) 1.7±12.8 - 0.5±3.4 - 2.4±15.3 
Azathioprine (N) 13 0 12 0 17 
dose / dose range (mg/day) a) 10±21.7/0-100 - 10.8±20.8 - 18.6±25.4 
dosing period (mg) a) 4.3±10.2 - 6.4±12.4 - 14.5±20.6 
Tacrolimus (N) 3 0 3 0 0 
dose / dose range (mg/day) a) 0.4±1.5 - 0.5±2.3 - 0 
dosing period (month) a) 0.8±3.5 - 0.5±3.2 - 0 
Anti-TNF-α agents (N) 4 0 5 0 25 
Infliximab (N) 4 - 5 - 19 
dose / dose range (mg/body) a) 18.7±72.8/0-380 - 22.4±75.6 - 165.5±188.2/0-400 
dosing period (month) a) 0.3±1.3 - 0.8±3.8 - 20.8±24.3 
adalimumab (N) 0 0 0 0 6 
dose / dose range (mg/body) a) - - - - 6.15±14.6/0-40 
dosing period (month) a) - - - - 1.1±3.6 
Enteral nutrition (N) 0 0 0 0 21 
dose / dose range (kcal/day) a) - - - - 415±535/0-2100 
dosing period (month) a) - - - - 16.9±37.3 
Food restriction therapy (N) 7 0 4 0 1 
period (day) a) 1.7±5.7 - 0.7±3.1 - 1.1±6.6 
Blood chemical findings           
Total protein (g/dl) a) 6.9±0.6/5.3-7.9  7.2±0.4/6.5-8.3 c) 6.9±0.5/4.7-8.0  7.2±0.4/6.4-8.4 d) 7.3±1.2/8.6-5.4 
Albumin (g/dl) a) 4.0±0.7/1.9-5.0 4.6±0.2/4.2-5.0 c) 4.1±0.6/1.7-4.8 4.6±0.2/4.1-5.1 d) 3.9±0.7/1.9-4.7 
Total cholesterol (mg/dl) a) 188±38.9/109-274  200±34.5/123-262  183±37.2/74-269 200±25.5/140-259 152.8±38.2/55-255 
BMI: body mass index, SASP: sulfasalazine, P: proctitis, LC: left-sided colitis, PC: pan-colitis, S: small bowel, C: colon, Both: small bowel & colon, CAI: Rachmilewitz index (a clinical activity index), 
CDAI: Crohn’s disease activity index. a): Body weight, BMI, dose and dosing period of each medication including enteral nutrition, period of food restriction test and data of biochemical findings are shown as 
the mean ± standard deviation together with the range. We could not obtain all data on the clinical record and reports of medical check-ups from all the subjects, and deficient data existed. Therefore, this table 
is composed of data obtained in this study. b): The bodyweight data of HV in training and validation set was shown using 57 HV samples except 3 samples. c): Serum total protein and albumin levels of HV were 
shown using 44 samples except 16 samples. d): Serum total protein and albumin levels of HV were shown using 42 samples except 18 samples. As far prednisolone, previous medication status of several 
samples was unclear because of their long disease durations and complicated treatment histories in several hospitals. Therefore, only reliable information we could check in our medical records was shown in 
this table; current dose and total dose within 1, 3, 6 months and 1 year. In our study, salicylates were medicated over entire disease duration in almost all cases except a few allergic cases, so their durations 
are not shown. 
Supplemental Table 11. Spearman’s rank correlation coefficients (rs) for the relationships between the various factor; body weight, body mass index and blood chemical findings, and all metabolites detected by 
GC-MS in the sera of HV. 
 
Bw  BMI TP Alb T-chol 
  rs P-value  rs P-value  rs P-value  rs P-value  rs P-value  
Pyruvate+oxalacetic acid 0.1529  0.1044  0.2098  0.0215  0.1835  0.0888  0.2944  0.0056  0.0682  0.4712  
Lactic acid 0.0813  0.3901  0.1171  0.2027  0.0426  0.6950  0.0009  0.9932  -0.0399  0.6735  
Glycolic acid 0.3574  <.0001 0.3425  0.0001  -0.2253  0.0359  -0.1460  0.1771  -0.0064  0.9464  
Alanine (2TMS) 0.2883  0.0019  0.2744  0.0024  0.1894  0.0789  0.2226  0.0382  0.1733  0.0652  
Hydroxybutyrate 0.1306  0.1661  0.2617  0.0039  0.3677  0.0005  0.2562  0.0166  0.0099  0.9166  
Oxalate -0.0094  0.9209  -0.0294  0.7496  0.0644  0.5532  0.0726  0.5041  -0.0541  0.5673  
Sarcosine 0.0594  0.5300  0.0467  0.6126  0.1496  0.1667  0.1392  0.1984  0.2125  0.0232  
2-Aminoisobutyrate 0.2116  0.0238  0.1411  0.1242  0.0115  0.9161  0.0858  0.4296  0.0161  0.8654  
3-Hydroxybutyrate -0.2487  0.0076  -0.1123  0.2222  0.2165  0.0440  -0.0216  0.8429  -0.1164  0.2176  
2-Aminobutyric acid 0.1430  0.1290  0.1209  0.1883  0.0389  0.7203  0.1186  0.2741  0.1696  0.0713  
Ketoisoleucine_1 0.4835  <.0001 0.4505  <.0001 0.2403  0.0250  0.4167  <.0001 0.0620  0.5120  
Malonic acid 0.1312  0.1640  0.0830  0.3675  0.0429  0.6932  0.0690  0.5254  -0.0667  0.4808  
3-Hydroxyisovaleric acid 0.2408  0.0099  0.1738  0.0576  0.1625  0.1326  0.2394  0.0256  -0.0083  0.9299  
Valine (2TMS) 0.5273  <.0001 0.4224  <.0001 0.0644  0.5532  0.2941  0.0057  0.0898  0.3423  
Urea 0.0398  0.6745  0.0732  0.4266  -0.0053  0.9615  -0.0019  0.9863  -0.1038  0.2719  
Oxamic acid -0.2477  0.0079  -0.2552  0.0049  0.0294  0.7872  -0.1198  0.2692  0.0523  0.5808  
2-Aminoethanol 0.3385  0.0002  0.3466  0.0001  0.0547  0.6150  0.0543  0.6176  0.2571  0.0058  
n-Caprylic acid -0.0643  0.4965  0.0026  0.9772  0.0416  0.7019  0.1063  0.3270  0.1520  0.1064  
Phosphate -0.2218  0.0177  -0.0589  0.5230  0.0499  0.6463  0.0411  0.7054  0.0058  0.9510  
Glycerol -0.3103  0.0008  -0.1218  0.1850  0.1871  0.0826  -0.0016  0.9879  -0.0847  0.3702  
Ethylmalonic acid 0.1022  0.2792  0.1444  0.1157  0.0505  0.6423  -0.0090  0.9342  -0.1721  0.0671  
Isoleucine 0.5053  <.0001 0.3963  <.0001 0.0647  0.5515  0.2640  0.0135  0.0718  0.4480  
Threonine (2TMS) 0.4989  <.0001 0.4032  <.0001 0.0494  0.6497  0.2538  0.0177  0.0826  0.3821  
Proline 0.2993  0.0012  0.2704  0.0028  -0.0751  0.4891  0.1306  0.2280  0.0263  0.7812  
Maleic acid 0.1099  0.2445  0.1510  0.0997  -0.0346  0.7505  -0.0680  0.5316  -0.1403  0.1366  
Glycine (3TMS) 0.0209  0.8255  0.0377  0.6824  -0.1703  0.1148  -0.0864  0.4259  0.1001  0.2893  
Succinic acid (or aldehyde) -0.1412  0.1339  0.0137  0.8820  0.1193  0.2712  0.1203  0.2670  0.1605  0.0880  
Catechol 0.0340  0.7199  0.0364  0.6932  0.0446  0.6820  0.1665  0.1233  -0.0114  0.9043  
Glyceric acid 0.1863  0.0472  0.1504  0.1010  -0.2198  0.0408  -0.0238  0.8269  0.1102  0.2432  
Uracil 0.1824  0.0521  0.1864  0.0415  -0.0449  0.6795  -0.0076  0.9442  -0.2215  0.0179  
Fumaric acid -0.0795  0.4005  0.0326  0.7235  0.2806  0.0085  0.2425  0.0236  0.1549  0.0999  
Serine (3TMS) -0.0958  0.3106  -0.1472  0.1085  0.0125  0.9083  0.2184  0.0421  0.1538  0.1023  
Nonanoic acid (C9) 0.2934  0.0015  0.2216  0.0150  0.0925  0.3943  0.1814  0.0926  0.2413  0.0097  
4-Methylbenzoic acid 0.1274  0.1769  0.1571  0.0867  0.0096  0.9296  0.0693  0.5238  0.0152  0.8722  
Glutaric acid 0.2369  0.0111  0.2469  0.0066  0.1215  0.2622  0.0659  0.5443  0.2058  0.0281  
Maleamic acid 0.1365  0.1474  0.1272  0.1662  -0.1737  0.1076  -0.0581  0.5930  0.0926  0.3273  
Prolinamide 0.0074  0.9380  0.0107  0.9073  -0.1017  0.3487  -0.1705  0.1143  -0.1242  0.1882  
Homoserine 0.0907  0.3372  0.0564  0.5405  0.0510  0.6392  0.1726  0.1100  0.0980  0.2994  
Malic acid 0.0235  0.8039  0.0794  0.3888  0.2597  0.0151  0.2766  0.0095  0.0732  0.4390  
Threitol 0.1617  0.0856  0.1373  0.1348  0.0098  0.9286  0.1307  0.2275  0.1300  0.1679  
meso-Erythritol 0.2151  0.0215  0.1789  0.0506  -0.0213  0.8445  0.1444  0.1821  0.1758  0.0613  
Adipic acid -0.1673  0.0751  -0.1182  0.1985  0.0039  0.9716  0.1046  0.3351  -0.1062  0.2605  
Acetylsalicylic acid 0.0752  0.4266  0.1385  0.1313  0.0642  0.5545  0.1467  0.1753  -0.0620  0.5125  
Aspartic acid 0.0294  0.7565  0.0553  0.5483  -0.0130  0.9051  0.1017  0.3484  0.1070  0.2571  
Methionine 0.3898  <.0001 0.2680  0.0031  -0.0414  0.7036  0.1330  0.2193  0.0845  0.3713  
trans-4-Hydroxy-L-proline 0.2091  0.0256  0.1601  0.0807  -0.1403  0.1949  -0.0040  0.9705  -0.0567  0.5488  
4-Aminobutyric acid 0.1687  0.0728  0.1832  0.0452  -0.0221  0.8389  0.1945  0.0710  0.2380  0.0108  
Pyrogallol -0.0399  0.6732  -0.0234  0.8001  -0.0478  0.6601  -0.0775  0.4754  0.0689  0.4661  
Creatinine 0.3056  0.0009  0.2833  0.0017  0.0882  0.4165  0.1374  0.2045  0.1472  0.1180  
Acetoacetic acid 0.3566  <.0001 0.2642  0.0036  0.0348  0.7491  0.2543  0.0175  0.1535  0.1030  
β-Glutamic acid 0.0925  0.3276  0.1335  0.1461  -0.0365  0.7369  -0.1098  0.3113  -0.2108  0.0244  
Glutamic acid 0.3135  0.0007  0.3339  0.0002  0.2406  0.0248  0.3015  0.0045  0.0928  0.3260  
Phenylalanine 0.3131  0.0007  0.3664  <.0001 0.1505  0.1642  0.1947  0.0707  0.1900  0.0428  
5-Aminovaleric acid 0.1227  0.1933  0.1174  0.2014  -0.1217  0.2616  0.0138  0.8992  0.1453  0.1230  
p-Hydroxybenzoic acid -0.2116  0.0238  -0.1121  0.2229  0.0047  0.9658  -0.0871  0.4227  -0.1144  0.2256  
Xylose_2 0.1074  0.2553  0.1086  0.2376  0.0041  0.9698  -0.0673  0.5355  -0.1308  0.1655  
threo-β-Hydroxyaspartic acid 0.2234  0.0169  0.1717  0.0607  -0.0486  0.6545  0.0953  0.3799  0.2048  0.0289  
Lyxose_2 0.0936  0.3220  0.1476  0.1076  0.0137  0.8998  0.0484  0.6565  0.2608  0.0051  
Arabinose -0.0231  0.8071  -0.0341  0.7117  0.1095  0.3127  0.1539  0.1547  0.0464  0.6237  
Lauric acid -0.4411  <.0001 -0.3193  0.0004  0.0944  0.3846  0.0105  0.9228  -0.0921  0.3296  
N-Acetyl-L-aspartic acid_2 -0.0688  0.4670  -0.0353  0.7022  -0.0132  0.9033  -0.1467  0.1750  -0.1359  0.1492  
Homocysteine_1 0.2085  0.0260  0.1615  0.0781  -0.0611  0.5738  0.1149  0.2894  -0.0237  0.8022  
Ribose 0.2370  0.0111  0.2132  0.0194  0.1739  0.1073  0.1477  0.1723  0.0981  0.2990  
Ribulose 0.1508  0.1092  0.1617  0.0778  0.1354  0.2110  0.1005  0.3544  0.1495  0.1124  
Asparagine 0.2222  0.0175  0.1211  0.1877  -0.0623  0.5664  0.1511  0.1625  0.0690  0.4655  
Taurine -0.0562  0.5524  0.0400  0.6643  0.2287  0.0331  0.1871  0.0827  0.1687  0.0727  
Cysteine sulfonic acid 0.1252  0.1845  0.1240  0.1773  -0.0236  0.8284  0.1683  0.1192  0.0285  0.7632  
Xylitol 0.3760  <.0001 0.4194  <.0001 0.1171  0.2802  0.2069  0.0545  0.0049  0.9584  
1,6-Anhydroglucose -0.0665  0.4819  -0.0524  0.5695  -0.1354  0.2110  0.0182  0.8669  0.1007  0.2862  
Arabitol 0.2959  0.0014  0.1874  0.0404  0.0483  0.6566  0.1616  0.1349  0.1057  0.2631  
Ribitol 0.3542  0.0001  0.2598  0.0042  0.1178  0.2770  0.2312  0.0312  -0.0879  0.3522  
Aconitate 0.0182  0.8473  0.0805  0.3823  0.1241  0.2521  0.0738  0.4972  0.2615  0.0050  
N-Acetyl-L-glutamate_1 0.2158  0.0211  0.2061  0.0239  -0.0613  0.5726  0.1973  0.0670  -0.0375  0.6922  
Glutamine 0.0944  0.3180  0.0044  0.9623  -0.0447  0.6809  0.1476  0.1726  0.2252  0.0160  
4-Hydroxymandelate -0.0888  0.3475  -0.1180  0.1992  -0.1983  0.0656  -0.0930  0.3917  0.0545  0.5645  
Dihydroorotate 0.0966  0.3065  0.0769  0.4041  -0.1245  0.2507  -0.1173  0.2791  -0.2348  0.0119  
O-Phosphoethanolamine -0.1684  0.0733  -0.0932  0.3111  0.0630  0.5620  0.1138  0.2939  -0.0530  0.5754  
Theanine_2 0.3119  0.0007  0.2807  0.0019  0.0985  0.3641  0.1257  0.2461  0.1676  0.0747  
Glycyl-glycine_1 0.0856  0.3650  0.1422  0.1212  0.0935  0.3889  0.0203  0.8517  0.0960  0.3094  
Citric acid + isocitric acid -0.2774  0.0028  -0.2149  0.0184  0.1832  0.0894  0.0308  0.7772  0.1282  0.1741  
Ornithine 0.1904  0.0425  0.1693  0.0645  0.0499  0.6461  0.2330  0.0299  0.1411  0.1343  
Hypoxanthine 0.1888  0.0442  0.2331  0.0104  0.1432  0.1858  0.1487  0.1693  0.0809  0.3923  
Citrulline 0.1905  0.0423  0.1041  0.2576  0.0864  0.4260  0.1303  0.2290  0.1950  0.0376  
1,5-Anhydro-D-glucitol 0.3449  0.0002  0.3031  0.0008  0.0525  0.6291  0.0729  0.5024  0.0636  0.5014  
Tagatose_2 (or psicose_2) -0.1292  0.1707  -0.0651  0.4802  0.1295  0.2318  0.0670  0.5376  0.0385  0.6845  
Fructose_1 0.1712  0.0685  0.0821  0.3726  -0.2776  0.0092  0.0517  0.6344  0.0118  0.9009  
2-Dehydro-D-gluconate_1 0.2035  0.0299  0.2168  0.0174  -0.0195  0.8576  0.0719  0.5078  0.1494  0.1126  
Glucose_1 0.0842  0.3733  0.1141  0.2145  0.0406  0.7090  -0.0041  0.9698  -0.0390  0.6804  
Sebacic acid 0.2484  0.0077  0.2449  0.0070  -0.0800  0.4616  0.0733  0.5001  -0.0177  0.8515  
Galactose_2 0.0891  0.3456  0.0544  0.5553  -0.0262  0.8095  0.0074  0.9460  -0.1549  0.0998  
Mannitol 0.1302  0.1675  0.0636  0.4904  -0.0847  0.4354  0.0802  0.4604  0.0801  0.3970  
Lysine (4TMS) 0.4870  <.0001 0.3765  <.0001 0.0424  0.6965  0.2893  0.0066  0.0903  0.3392  
Galactosamine_1 0.1606  0.0878  0.1384  0.1316  0.0206  0.8500  0.2237  0.0372  0.0040  0.9660  
Histidine 0.2970  0.0013  0.2140  0.0189  -0.0458  0.6736  0.1519  0.1603  0.1321  0.1612  
Glucuronate_1 0.3183  0.0006  0.2963  0.0010  0.2065  0.0550  0.3325  0.0017  0.3121  0.0007  
5-Keto-D-gluconate_2 -0.3920  <.0001 -0.3805  <.0001 -0.0181  0.8681  -0.1941  0.0716  -0.0780  0.4095  
Galacturonic acid_1 -0.0127  0.8932  -0.0102  0.9118  -0.0007  0.9951  0.0871  0.4225  0.1245  0.1869  
Tyrosine 0.4218  <.0001 0.4288  <.0001 0.0228  0.8339  0.0916  0.3990  0.1038  0.2716  
Pantothenate 0.1377  0.1439  0.1460  0.1117  -0.0143  0.8956  0.0885  0.4152  0.1309  0.1649  
N-α-Acetyl-L-ornithine_2 0.0903  0.3393  0.0661  0.4733  0.0469  0.6665  -0.0323  0.7667  -0.0308  0.7451  
Glucarate 0.1039  0.2715  0.0840  0.3618  -0.0697  0.5211  0.1086  0.3168  0.0828  0.3813  
S-Benzyl-L-cysteine_1 0.3117  0.0007  0.2527  0.0054  0.1224  0.2586  0.1754  0.1041  0.1902  0.0427  
Xanthine 0.2643  0.0045  0.3420  0.0001  0.2556  0.0169  0.2038  0.0583  0.1389  0.1405  
Palmitoleate -0.2339  0.0123  -0.1222  0.1835  0.2326  0.0302  0.0951  0.3808  0.0098  0.9178  
Inositol 0.0995  0.2921  0.1203  0.1907  0.1008  0.3530  0.1440  0.1832  0.1904  0.0424  
Dopa 0.1540  0.1019  0.1928  0.0349  0.0200  0.8540  0.1110  0.3062  0.0270  0.7756  
Uric acid 0.5227  <.0001 0.4896  <.0001 0.0448  0.6802  0.3149  0.0030  0.1218  0.1967  
N-α-Acetyl-L-lysine_2 0.2358  0.0116  0.2757  0.0023  0.1934  0.0727  0.2399  0.0252  0.1172  0.2144  
Heptadecanoate 0.0509  0.5905  0.0567  0.5384  -0.0437  0.6876  0.1166  0.2821  0.0840  0.3740  
Kynurenine 0.2216  0.0178  0.2131  0.0194  -0.0153  0.8881  0.1443  0.1825  0.0115  0.9034  
Cystathionine 0.2413  0.0097  0.2521  0.0055  0.0384  0.7237  0.0834  0.4427  0.1236  0.1900  
Cystamine 0.3516  0.0001  0.4018  <.0001 -0.0187  0.8636  0.0519  0.6330  0.0865  0.3602  
Tryptophan 0.2922  0.0016  0.2001  0.0284  -0.0285  0.7931  0.2119  0.0488  0.2501  0.0073  
Elaidic acid -0.2076  0.0266  -0.0702  0.4464  0.2392  0.0256  0.0699  0.5201  0.0393  0.6780  
Homocysteine 0.0587  0.5347  0.0333  0.7180  0.0228  0.8338  0.1049  0.3338  0.0816  0.3880  
Spearman’s rank correlation coefficients (rs) were calculated for the relationships between the various factors; i.e., body weight (Bw, kg) and body mass index (BMI), or blood chemical findings; i.e., 
the serum levels of total protein (TP, g/dl), albumin (Alb, g/dl) and total cholesterol (T-chol, mg/dl), and the all metabolites detected by GC-MS in HV. The data of Bw, TP and Alb could not be obtained from 
reports of medical check-ups of all the subjects; Bw was not measured in 3 of 120 samples. The serum levels of TP and Alb were not measured in 34 of 120 samples. Therefore, this table is composed of only 
data obtained in this study. 
 
 
 
 
 
 
 
Supplemental Table 12. Spearman’s rank correlation coefficients (rs) for the relationships between medications; i.e., salicylates and azathioprine, and all metabolites detected by GC-MS in the sera of UCr. 
 
salicylates azathioprine 
 
Pentasa Asacol SASP 
  
  rs P-value  rs P-value  rs P-value  rs P-value  
Pyruvate+oxalacetic acid -0.0383  0.8526  0.4364  0.2797  0.2554  0.5415  0.0976  0.5335  
Lactic acid 0.1822  0.3731  0.5455  0.1619  0.7407  0.0356  0.2874  0.0617  
Glycolic acid 0.3629  0.0684  -0.4364  0.2797  -0.3193  0.4408  0.1972  0.2050  
Alanine (2TMS) -0.0515  0.8025  0.1091  0.7970  -0.1277  0.7631  0.0371  0.8131  
Hydroxybutyrate 0.0115  0.9556  -0.3273  0.4287  -0.0383  0.9282  -0.1451  0.3531  
Oxalate -0.0522  0.7999  -0.2182  0.6036  -0.0639  0.8806  -0.1239  0.4284  
Sarcosine -0.0341  0.8685  0.1091  0.7970  -0.1660  0.6944  -0.1223  0.4346  
2-Aminoisobutyrate -0.3107  0.1224  -0.6547  0.0781  -0.1149  0.7864  -0.2028  0.1920  
3-Hydroxybutyrate 0.0164  0.9367  -0.2182  0.6036  0.3576  0.3845  -0.2074  0.1821  
2-Aminobutyric acid 0.0338  0.8698  -0.3273  0.4287  -0.3448  0.4029  -0.1576  0.3129  
Ketoisoleucine_1 0.1226  0.5507  0.3273  0.4287  0.2554  0.5415  0.2199  0.1565  
Malonic acid 0.2205  0.2791  -0.6547  0.0781  0.0639  0.8806  0.2830  0.0659  
3-Hydroxyisovaleric acid 0.1641  0.4232  -0.4364  0.2797  0.1405  0.7401  0.2224  0.1517  
Valine (2TMS) -0.0432  0.8341  0.0000  1.0000  -0.3959  0.3316  -0.0876  0.5766  
Urea 0.2703  0.1817  -0.1091  0.7970  0.4980  0.2091  0.2328  0.1330  
Oxamic acid 0.0798  0.6985  -0.6547  0.0781  0.3448  0.4029  0.2811  0.0678  
2-Aminoethanol -0.0522  0.7999  -0.2182  0.6036  -0.4214  0.2984  -0.0888  0.5711  
n-Caprylic acid 0.1331  0.5170  0.3273  0.4287  -0.1405  0.7401  -0.0719  0.6469  
Phosphate 0.0031  0.9879  0.1091  0.7970  0.6257  0.0970  0.0606  0.6995  
Glycerol 0.2010  0.3249  0.0000  1.0000  0.4853  0.2229  -0.1147  0.4641  
Ethylmalonic acid 0.1811  0.3759  0.0000  1.0000  0.8428  0.0086  0.2680  0.0823  
Isoleucine -0.0599  0.7713  0.1091  0.7970  -0.5108  0.1958  -0.0708  0.6521  
Threonine (2TMS) -0.0822  0.6897  0.1091  0.7970  -0.3703  0.3665  -0.0790  0.6144  
Proline -0.2170  0.2870  0.0000  1.0000  -0.3320  0.4217  -0.1287  0.4108  
Maleic acid 0.1703  0.4055  0.0000  1.0000  0.7024  0.0521  0.2124  0.1715  
Glycine (3TMS) -0.1292  0.5292  -0.4364  0.2797  -0.7790  0.0227  0.0393  0.8026  
Succinic acid (or aldehyde) -0.1898  0.3530  -0.1091  0.7970  -0.0766  0.8569  -0.1123  0.4735  
Catechol 0.6681  0.0002  -0.2182  0.6036  0.5236  0.1829  -0.0591  0.7066  
Glyceric acid 0.0456  0.8248  0.1091  0.7970  -0.1022  0.8098  0.2400  0.1211  
Uracil 0.0188  0.9273  -0.3273  0.4287  0.0511  0.9044  0.2345  0.1302  
Fumaric acid -0.2734  0.1765  -0.1091  0.7970  -0.1916  0.6495  0.0617  0.6942  
Serine (3TMS) -0.1634  0.4252  -0.4364  0.2797  -0.3065  0.4603  -0.1847  0.2358  
Nonanoic acid (C9) 0.2790  0.1675  0.3273  0.4287  0.4853  0.2229  0.1371  0.3806  
4-Methylbenzoic acid 0.2577  0.2036  0.4364  0.2797  0.8556  0.0067  -0.0497  0.7517  
Glutaric acid 0.0815  0.6922  0.0000  1.0000  0.2043  0.6274  0.0056  0.9713  
Maleamic acid -0.1846  0.3666  -0.7638  0.0274  0.0000  1.0000  -0.0639  0.6842  
Prolinamide 0.2480  0.2219  -0.3273  0.4287  0.0639  0.8806  0.2722  0.0774  
Homoserine 0.0791  0.7010  -0.2182  0.6036  -0.0894  0.8333  0.0891  0.5701  
Malic acid -0.2076  0.3089  -0.1091  0.7970  -0.4470  0.2669  0.1490  0.3402  
Threitol -0.1616  0.4303  0.3273  0.4287  -0.8939  0.0028  0.1471  0.3464  
meso-Erythritol 0.1376  0.5027  -0.2182  0.6036  -0.3320  0.4217  -0.1410  0.3671  
Adipic acid 0.2661  0.1888  -0.1091  0.7970  0.6385  0.0884  -0.0016  0.9917  
Acetylsalicylic acid 0.3281  0.1018  0.6547  0.0781  0.1405  0.7401  0.0247  0.8750  
Aspartic acid 0.0070  0.9731  -0.1091  0.7970  -0.2299  0.5839  0.0980  0.5319  
Methionine -0.0832  0.6860  -0.1091  0.7970  -0.3320  0.4217  0.0223  0.8870  
trans-4-Hydroxy-L-proline -0.0226  0.9126  -0.2182  0.6036  -0.7534  0.0309  -0.1591  0.3083  
4-Aminobutyric acid -0.3535  0.0764  0.0000  1.0000  -0.7918  0.0192  0.0073  0.9631  
Pyrogallol -0.0766  0.7098  0.0000  1.0000  -0.4725  0.2371  0.0312  0.8424  
Creatinine 0.0077  0.9704  -0.1091  0.7970  -0.4725  0.2371  -0.0092  0.9535  
Acetoacetic acid 0.3225  0.1081  0.1091  0.7970  0.3959  0.3316  -0.0394  0.8020  
β-Glutamic acid 0.3253  0.1049  -0.1091  0.7970  0.7024  0.0521  0.2520  0.1030  
Glutamic acid 0.0596  0.7726  0.2182  0.6036  -0.6385  0.0884  -0.1094  0.4850  
Phenylalanine -0.1324  0.5192  0.1091  0.7970  -0.3703  0.3665  -0.0730  0.6417  
5-Aminovaleric acid 0.1700  0.4065  -0.2182  0.6036  -0.2937  0.4801  -0.1810  0.2454  
p-Hydroxybenzoic acid 0.3577  0.0728  0.2182  0.6036  0.7790  0.0227  0.0751  0.6320  
Xylose_2 -0.0418  0.8393  -0.2182  0.6036  -0.7024  0.0521  0.1722  0.2694  
threo-β-Hydroxyaspartic acid 0.0056  0.9784  -0.1091  0.7970  -0.0383  0.9282  0.3363  0.0274  
Lyxose_2 0.0132  0.9488  -0.8729  0.0047  0.3065  0.4603  0.0681  0.6643  
Arabinose -0.0888  0.6661  -0.3273  0.4287  -0.7790  0.0227  -0.1853  0.2342  
Lauric acid -0.0871  0.6723  -0.1091  0.7970  0.0894  0.8333  -0.2056  0.1859  
N-Acetyl-L-aspartic acid_2 0.2118  0.2990  0.2182  0.6036  0.6385  0.0884  0.0745  0.6349  
Homocysteine_1 0.2679  0.1859  -0.2182  0.6036  0.6385  0.0884  0.2782  0.0708  
Ribose -0.0571  0.7816  -0.1091  0.7970  -0.6002  0.1157  -0.1673  0.2834  
Ribulose -0.2494  0.2192  0.0000  1.0000  -0.2682  0.5208  -0.1217  0.4370  
Asparagine -0.2929  0.1464  -0.6547  0.0781  -0.6385  0.0884  0.0222  0.8876  
Taurine -0.0038  0.9852  0.1091  0.7970  -0.0383  0.9282  -0.2830  0.0659  
Cysteine sulfonic acid -0.3020  0.1338  -0.3273  0.4287  0.1660  0.6944  0.3052  0.0466  
Xylitol 0.1376  0.5027  0.1091  0.7970  0.5236  0.1829  0.0133  0.9326  
1,6-Anhydroglucose 0.0307  0.8818  -0.1091  0.7970  -0.2937  0.4801  0.0942  0.5479  
Arabitol 0.1059  0.6067  0.1091  0.7970  0.2682  0.5208  -0.1152  0.4621  
Ribitol -0.0132  0.9488  0.3273  0.4287  0.3065  0.4603  0.0785  0.6167  
Aconitate 0.0829  0.6872  0.5455  0.1619  -0.4853  0.2229  0.0147  0.9256  
N-Acetyl-L-glutamate_1 0.2995  0.1371  -0.1091  0.7970  -0.0128  0.9761  0.0327  0.8349  
Glutamine -0.0947  0.6453  -0.1091  0.7970  -0.3448  0.4029  -0.0237  0.8800  
4-Hydroxymandelate -0.2790  0.1675  -0.5455  0.1619  -0.8301  0.0108  -0.0447  0.7761  
Dihydroorotate 0.1794  0.3806  -0.5455  0.1619  -0.2043  0.6274  0.1420  0.3637  
O-Phosphoethanolamine -0.0098  0.9623  0.1091  0.7970  0.4214  0.2984  0.0763  0.6269  
Theanine_2 0.1978  0.3326  0.5455  0.1619  0.6385  0.0884  0.1099  0.4830  
Glycyl-glycine_1 0.0324  0.8752  -0.1091  0.7970  -0.3703  0.3665  -0.1334  0.3939  
Citric acid + isocitric acid -0.1209  0.5564  0.2182  0.6036  -0.2682  0.5208  0.0573  0.7150  
Ornithine -0.0195  0.9247  -0.2182  0.6036  -0.5491  0.1586  -0.0680  0.6649  
Hypoxanthine 0.1843  0.3676  0.3273  0.4287  -0.1916  0.6495  -0.0613  0.6960  
Citrulline -0.1459  0.4768  -0.3273  0.4287  -0.7790  0.0227  -0.0957  0.5415  
1,5-Anhydro-D-glucitol 0.0906  0.6600  -0.2182  0.6036  -0.6641  0.0725  -0.0982  0.5309  
Tagatose_2 (or psicose_2) -0.0247  0.9046  0.0000  1.0000  0.2937  0.4801  -0.1557  0.3188  
Fructose_1 -0.0195  0.9247  0.4364  0.2797  -0.3448  0.4029  -0.0898  0.5668  
2-Dehydro-D-gluconate_1 0.0254  0.9019  0.1091  0.7970  0.0255  0.9521  -0.2311  0.1360  
Glucose_1 0.2807  0.1648  -0.1091  0.7970  0.4980  0.2091  0.2274  0.1424  
Sebacic acid 0.2139  0.2942  0.1091  0.7970  0.2937  0.4801  -0.0754  0.6309  
Galactose_2 0.2166  0.2878  0.8729  0.0047  0.7407  0.0356  0.1423  0.3628  
Mannitol 0.1250  0.5428  0.0000  1.0000  -0.4086  0.3148  -0.1781  0.2531  
Lysine (4TMS) -0.2083  0.3072  -0.5455  0.1619  -0.8301  0.0108  -0.0161  0.9186  
Galactosamine_1 0.2198  0.2807  -0.2182  0.6036  -0.1277  0.7631  -0.0236  0.8807  
Histidine -0.2264  0.2661  -0.1091  0.7970  -0.4980  0.2091  -0.1465  0.3485  
Glucuronate_1 -0.2274  0.2638  -0.1091  0.7970  0.2809  0.5003  -0.3410  0.0253  
5-Keto-D-gluconate_2 0.0920  0.6550  -0.7638  0.0274  -0.0511  0.9044  0.2351  0.1291  
Galacturonic acid_1 0.1449  0.4800  0.2182  0.6036  0.6385  0.0884  0.0583  0.7102  
Tyrosine -0.0331  0.8725  -0.2182  0.6036  -0.5619  0.1472  0.0749  0.6331  
Pantothenate 0.0902  0.6612  -0.2182  0.6036  0.4086  0.3148  0.0632  0.6871  
N-α-Acetyl-L-ornithine_2 0.3243  0.1061  -0.1091  0.7970  0.7024  0.0521  0.2520  0.1030  
Glucarate 0.0784  0.7035  0.1091  0.7970  -0.2299  0.5839  -0.0957  0.5415  
S-Benzyl-L-cysteine_1 0.2302  0.2578  0.3273  0.4287  0.4086  0.3148  0.2128  0.1708  
Xanthine 0.2853  0.1578  0.1091  0.7970  -0.0511  0.9044  -0.0856  0.5854  
Palmitoleate 0.0568  0.7829  -0.4364  0.2797  0.5491  0.1586  -0.0015  0.9924  
Inositol -0.2104  0.3023  -0.4364  0.2797  -0.3703  0.3665  -0.1017  0.5162  
Dopa 0.2870  0.1551  0.2182  0.6036  0.7024  0.0521  0.2406  0.1201  
Uric acid 0.0313  0.8792  0.2182  0.6036  -0.1916  0.6495  0.0083  0.9580  
N-α-Acetyl-L-lysine_2 0.1069  0.6031  -0.7638  0.0274  -0.2682  0.5208  0.3465  0.0228  
Heptadecanoate -0.1794  0.3806  -0.1091  0.7970  0.2554  0.5415  -0.1508  0.3345  
Kynurenine 0.1947  0.3405  -0.2182  0.6036  -0.0894  0.8333  0.1277  0.4144  
Cystathionine 0.0850  0.6798  -0.6547  0.0781  0.1532  0.7171  0.2180  0.1602  
Cystamine 0.3379  0.0914  -0.2182  0.6036  0.3576  0.3845  0.1357  0.3855  
Tryptophan -0.0167  0.9354  -0.1091  0.7970  -0.1277  0.7631  0.0144  0.9268  
Elaidic acid 0.2783  0.1686  0.0000  1.0000  0.3703  0.3665  0.0623  0.6912  
Homocysteine 0.1449  0.4800  0.2182  0.6036  0.6385  0.0884  0.0583  0.7102  
Spearman’s rank correlation coefficients (rs) were calculated for the relationships between current dose including 0 mg of medication; i.e., each salicylates; Pentasa (N=26), Asacol (N=8) and SASP (N=8), or 
azathioprine (N=39) without steroid, other immunomodulatory agents and biological agents, and all metabolites detected by GC-MS in the sera of UCr. As far steroid only, previous medication status of several 
samples is unclear because of their long disease durations and complicated treatment histories in several hospitals. However, we could check those of steroid within a year in our medical records reliably. 
Therefore, the sample not medicated with steroid within the range of a year was treated as a non-administrated sample. As far salicylates, correlation coefficients (rs) of dose of each salicylates without other 
medication including immunomoduratoy agents were calculated. All samples of the patients medicated with azathioprine were compared with those with salicylates, so correlation coefficients (rs) of dose of 
azathioprine with salicylates were calculated.  
 
 
 
 
 
Supplemental Table 13. Spearman’s rank correlation coefficients (rs) for the relationships between steroid and all metabolites detected by GC-MS in the sera of UCr. 
  Current dose   Total dose               
   
for 1 month   for 3 months   for 6 months   for 1 year   
  rs P-value  rs P-value  rs P-value  rs P-value  rs P-value  
Pyruvate+oxalacetic acid 0.3033  0.0453  0.3015  0.0467  0.3303  0.0305  0.2645  0.0865  0.2825  0.0664  
Lactic acid 0.4176  0.0048  0.4161  0.0050  0.4288  0.0041  0.4443  0.0028  0.4662  0.0016  
Glycolic acid -0.1205  0.4358  -0.1131  0.4650  -0.1015  0.5172  -0.0090  0.9541  0.0254  0.8718  
Alanine (2TMS) 0.0859  0.5793  0.0685  0.6585  0.0887  0.5715  0.0864  0.5815  0.0578  0.7126  
Hydroxybutyrate 0.3393  0.0243  0.3466  0.0212  0.3446  0.0236  0.2558  0.0978  0.2180  0.1602  
Oxalate -0.1399  0.3650  -0.1296  0.4018  -0.1083  0.4895  -0.0386  0.8057  0.0449  0.7748  
Sarcosine 0.1413  0.3602  0.1466  0.3423  0.1702  0.2753  0.0898  0.5667  0.0169  0.9143  
2-Aminoisobutyrate -0.1705  0.2685  -0.1765  0.2518  -0.1576  0.3127  -0.1349  0.3883  -0.0863  0.5821  
3-Hydroxybutyrate 0.3090  0.0413  0.3139  0.0380  0.3100  0.0430  0.2812  0.0678  0.2618  0.0899  
2-Aminobutyric acid 0.0899  0.5616  0.0821  0.5962  0.0845  0.5902  -0.0231  0.8829  -0.0830  0.5968  
Ketoisoleucine_1 0.3024  0.0460  0.3065  0.0430  0.3261  0.0329  0.2603  0.0919  0.2531  0.1015  
Malonic acid 0.1637  0.2885  0.1707  0.2679  0.1697  0.2767  0.1975  0.2042  0.2716  0.0781  
3-Hydroxyisovaleric acid 0.0838  0.5887  0.0869  0.5747  0.0669  0.6698  0.0729  0.6421  0.1150  0.4627  
Valine (2TMS) 0.1404  0.3634  0.1329  0.3898  0.1574  0.3134  0.0544  0.7291  -0.0178  0.9098  
Urea 0.1323  0.3918  0.1298  0.4009  0.1378  0.3780  0.1971  0.2053  0.2663  0.0844  
Oxamic acid 0.1647  0.2853  0.1668  0.2792  0.1872  0.2293  0.1488  0.3409  0.1146  0.4645  
2-Aminoethanol -0.0344  0.8246  -0.0468  0.7630  -0.0243  0.8770  -0.0742  0.6362  -0.0994  0.5258  
n-Caprylic acid -0.0999  0.5190  -0.0853  0.5820  -0.0607  0.6992  -0.1133  0.4693  -0.0692  0.6594  
Phosphate 0.1693  0.2718  0.1760  0.2531  0.1767  0.2570  0.2498  0.1062  0.2218  0.1529  
Glycerol 0.2326  0.1287  0.2392  0.1178  0.2589  0.0937  0.2031  0.1916  0.1766  0.2572  
Ethylmalonic acid 0.1008  0.5150  0.1071  0.4888  0.1053  0.5017  0.1223  0.4348  0.1537  0.3251  
Isoleucine 0.1791  0.2446  0.1805  0.2410  0.2000  0.1985  0.0896  0.5677  0.0316  0.8406  
Threonine (2TMS) 0.1477  0.3387  0.1498  0.3318  0.1689  0.2789  0.0598  0.7034  0.0000  1.0000  
Proline -0.0912  0.5559  -0.0986  0.5241  -0.0842  0.5913  -0.1359  0.3849  -0.1715  0.2715  
Maleic acid 0.1669  0.2790  0.1579  0.3059  0.1571  0.3142  0.1526  0.3287  0.1675  0.2830  
Glycine (3TMS) -0.1301  0.3999  -0.1418  0.3587  -0.1261  0.4205  -0.0352  0.8225  -0.0892  0.5695  
Succinic acid (or aldehyde) -0.0450  0.7717  -0.0560  0.7181  -0.0612  0.6969  -0.0413  0.7924  -0.0113  0.9424  
Catechol 0.0538  0.7289  0.0591  0.7033  0.0669  0.6698  0.1231  0.4317  0.1223  0.4345  
Glyceric acid 0.1058  0.4945  0.1146  0.4589  0.0822  0.6002  0.1658  0.2879  0.2296  0.1387  
Uracil 0.1449  0.3481  0.1427  0.3555  0.1158  0.4597  0.1919  0.2176  0.2587  0.0939  
Fumaric acid 0.0960  0.5355  0.0988  0.5236  0.1228  0.4327  0.0860  0.5836  0.0087  0.9560  
Serine (3TMS) 0.0118  0.9393  0.0019  0.9903  -0.0208  0.8947  -0.0873  0.5779  -0.1608  0.3029  
Nonanoic acid (C9) 0.1787  0.2459  0.1843  0.2311  0.2143  0.1676  0.1786  0.2517  0.1159  0.4593  
4-Methylbenzoic acid 0.0357  0.8181  0.0243  0.8754  0.0190  0.9035  0.0114  0.9422  -0.0222  0.8874  
Glutaric acid 0.0827  0.5935  0.0901  0.5607  0.1060  0.4986  0.1788  0.2514  0.1824  0.2417  
Maleamic acid 0.4625  0.0016  0.4627  0.0016  0.4559  0.0021  0.4914  0.0008  0.4687  0.0015  
Prolinamide 0.1472  0.3402  0.1546  0.3162  0.1539  0.3245  0.1780  0.2533  0.2525  0.1024  
Homoserine 0.1022  0.5091  0.1001  0.5181  0.0855  0.5858  0.1198  0.4442  0.1731  0.2671  
Malic acid 0.3982  0.0074  0.4024  0.0068  0.4025  0.0075  0.3257  0.0331  0.2442  0.1145  
Threitol -0.2440  0.1104  -0.2411  0.1149  -0.2263  0.1445  -0.1340  0.3916  -0.1375  0.3794  
meso-Erythritol 0.0876  0.5720  0.0960  0.5352  0.1211  0.4394  0.0594  0.7050  0.0803  0.6087  
Adipic acid -0.0314  0.8395  -0.0396  0.7987  -0.0479  0.7605  0.0294  0.8517  0.0972  0.5352  
Acetylsalicylic acid -0.0144  0.9260  -0.0126  0.9351  0.0155  0.9212  0.0190  0.9036  0.0474  0.7629  
Aspartic acid 0.1670  0.2787  0.1496  0.3326  0.1519  0.3309  0.1270  0.4172  0.0672  0.6686  
Methionine 0.1166  0.4509  0.0978  0.5276  0.0877  0.5759  0.0240  0.8788  -0.0387  0.8054  
trans-4-Hydroxy-L-proline -0.1002  0.5175  -0.1179  0.4460  -0.1098  0.4834  -0.1534  0.3261  -0.1639  0.2935  
4-Aminobutyric acid 0.0273  0.8604  0.0315  0.8389  0.0376  0.8108  0.0913  0.5606  0.1564  0.3166  
Pyrogallol -0.1605  0.2981  -0.1682  0.2750  -0.1526  0.3285  -0.0902  0.5651  -0.1230  0.4320  
Creatinine -0.0486  0.7542  -0.0652  0.6741  -0.0779  0.6193  -0.1521  0.3302  -0.2011  0.1960  
Acetoacetic acid -0.0772  0.6186  -0.0835  0.5899  -0.1208  0.4403  -0.1459  0.3506  -0.1090  0.4866  
β-Glutamic acid 0.2440  0.1104  0.2443  0.1100  0.2514  0.1039  0.2445  0.1140  0.3156  0.0392  
Glutamic acid 0.2855  0.0603  0.2730  0.0730  0.2466  0.1109  0.2331  0.1325  0.2545  0.0996  
Phenylalanine 0.2244  0.1431  0.2102  0.1709  0.2043  0.1889  0.1373  0.3800  0.0934  0.5513  
5-Aminovaleric acid 0.0711  0.6463  0.0640  0.6797  0.0659  0.6745  -0.0261  0.8682  -0.0845  0.5899  
p-Hydroxybenzoic acid 0.0736  0.6349  0.0729  0.6382  0.0915  0.5596  0.1581  0.3113  0.1659  0.2876  
Xylose_2 0.2278  0.1369  0.2373  0.1209  0.2251  0.1468  0.1732  0.2666  0.1686  0.2798  
threo-β-Hydroxyaspartic acid -0.0236  0.8790  -0.0201  0.8971  -0.0188  0.9048  -0.0648  0.6796  -0.0888  0.5714  
Lyxose_2 0.0609  0.6948  0.0509  0.7427  0.0298  0.8494  0.0194  0.9018  0.0198  0.8997  
Arabinose 0.0077  0.9605  -0.0083  0.9575  -0.0055  0.9720  -0.0773  0.6223  -0.0214  0.8919  
Lauric acid -0.1798  0.2427  -0.1685  0.2744  -0.1664  0.2862  -0.1877  0.2281  -0.0959  0.5408  
N-Acetyl-L-aspartic acid_2 -0.0086  0.9557  -0.0154  0.9212  -0.0135  0.9314  0.0734  0.6399  0.0956  0.5418  
Homocysteine_1 0.1359  0.3791  0.1429  0.3546  0.1429  0.3608  0.1627  0.2973  0.2013  0.1955  
Ribose -0.0865  0.5766  -0.0900  0.5612  -0.0669  0.6698  -0.1497  0.3379  -0.1584  0.3104  
Ribulose -0.2269  0.1386  -0.2452  0.1086  -0.2348  0.1295  -0.3082  0.0444  -0.3572  0.0187  
Asparagine -0.0099  0.9490  -0.0245  0.8748  -0.0281  0.8582  -0.1177  0.4523  -0.1969  0.2058  
Taurine 0.0265  0.8646  0.0250  0.8718  -0.0020  0.9898  -0.0653  0.6774  -0.1303  0.4048  
Cysteine sulfonic acid 0.1282  0.4069  0.1360  0.3788  0.1353  0.3869  0.1647  0.2914  0.2124  0.1714  
Xylitol 0.2298  0.1334  0.2347  0.1251  0.2193  0.1577  0.1186  0.4487  0.1061  0.4983  
1,6-Anhydroglucose 0.0052  0.9733  -0.0086  0.9557  0.0115  0.9415  0.0590  0.7073  0.0823  0.5998  
Arabitol 0.1026  0.5076  0.1118  0.4702  0.1531  0.3269  0.1293  0.4086  0.0734  0.6399  
Ribitol 0.3211  0.0336  0.3252  0.0312  0.3323  0.0295  0.3042  0.0473  0.2382  0.1239  
Aconitate 0.1381  0.3712  0.1232  0.4256  0.1629  0.2966  0.0994  0.5261  0.0970  0.5361  
N-Acetyl-L-glutamate_1 0.2276  0.1373  0.2339  0.1265  0.2561  0.0973  0.1514  0.3325  0.1335  0.3935  
Glutamine -0.1703  0.2691  -0.1840  0.2317  -0.1800  0.2482  -0.2224  0.1517  -0.2809  0.0680  
4-Hydroxymandelate -0.1595  0.3010  -0.1708  0.2676  -0.1431  0.3599  -0.1663  0.2865  -0.1597  0.3063  
Dihydroorotate 0.0013  0.9933  0.0084  0.9569  0.0195  0.9010  0.1021  0.5149  0.1806  0.2464  
O-Phosphoethanolamine -0.0661  0.6701  -0.0512  0.7416  -0.0328  0.8344  -0.0162  0.9178  0.0391  0.8032  
Theanine_2 0.1793  0.2443  0.1746  0.2570  0.1835  0.2389  0.2322  0.1341  0.3003  0.0504  
Glycyl-glycine_1 -0.0130  0.9333  -0.0038  0.9806  0.0000  1.0000  0.0870  0.5790  0.1221  0.4353  
Citric acid + isocitric acid -0.2204  0.1506  -0.2306  0.1321  -0.2068  0.1834  -0.2193  0.1577  -0.2124  0.1714  
Ornithine -0.0254  0.8700  -0.0445  0.7741  -0.0266  0.8657  -0.0001  0.9994  -0.0087  0.9560  
Hypoxanthine 0.0002  0.9988  0.0119  0.9387  0.0005  0.9975  -0.0015  0.9922  0.0385  0.8065  
Citrulline -0.1614  0.2952  -0.1763  0.2524  -0.1734  0.2660  -0.1866  0.2308  -0.1862  0.2319  
1,5-Anhydro-D-glucitol -0.2308  0.1318  -0.2335  0.1271  -0.2368  0.1262  -0.1838  0.2381  -0.1428  0.3610  
Tagatose_2 (or psicose_2) 0.0422  0.7857  0.0549  0.7232  0.0459  0.7702  0.0548  0.7268  0.0674  0.6676  
Fructose_1 0.0086  0.9557  0.0274  0.8598  0.0218  0.8896  -0.0721  0.6459  -0.1050  0.5028  
2-Dehydro-D-gluconate_1 0.3707  0.0132  0.3706  0.0133  0.3546  0.0196  0.2476  0.1095  0.1811  0.2452  
Glucose_1 0.1319  0.3935  0.1294  0.4027  0.1386  0.3754  0.1934  0.2139  0.2583  0.0945  
Sebacic acid -0.0069  0.9648  -0.0139  0.9284  -0.0010  0.9949  -0.0029  0.9851  0.0151  0.9233  
Galactose_2 0.1776  0.2488  0.1793  0.2441  0.1792  0.2502  0.0944  0.5470  0.0865  0.5811  
Mannitol -0.0718  0.6430  -0.0782  0.6139  -0.0629  0.6886  -0.0534  0.7336  -0.1061  0.4983  
Lysine (4TMS) 0.0228  0.8832  0.0047  0.9757  -0.0098  0.9504  -0.0898  0.5667  -0.1495  0.3387  
Galactosamine_1 0.2303  0.1326  0.2302  0.1327  0.2323  0.1338  0.1139  0.4670  0.0787  0.6157  
Histidine -0.3309  0.0283  -0.3407  0.0236  -0.3429  0.0244  -0.4163  0.0055  -0.4685  0.0015  
Glucuronate_1 0.1095  0.4791  0.1028  0.5068  0.1291  0.4094  0.0209  0.8941  0.0194  0.9020  
5-Keto-D-gluconate_2 0.0783  0.6132  0.0861  0.5783  0.0965  0.5382  0.0998  0.5242  0.1315  0.4007  
Galacturonic acid_1 0.0591  0.7032  0.0516  0.7393  0.0561  0.7207  0.1409  0.3673  0.1526  0.3286  
Tyrosine -0.0087  0.9551  -0.0169  0.9133  -0.0095  0.9517  -0.1038  0.5076  -0.1103  0.4812  
Pantothenate 0.0567  0.7146  0.0790  0.6101  0.0805  0.6081  0.1655  0.2889  0.1722  0.2696  
N-α-Acetyl-L-ornithine_2 0.2440  0.1104  0.2443  0.1100  0.2514  0.1039  0.2445  0.1140  0.3156  0.0392  
Glucarate -0.1755  0.2546  -0.1687  0.2737  -0.1729  0.2674  -0.2281  0.1413  -0.2118  0.1728  
S-Benzyl-L-cysteine_1 -0.1470  0.3410  -0.1537  0.3192  -0.1574  0.3134  -0.1773  0.2552  -0.1998  0.1991  
Xanthine 0.2783  0.0674  0.2761  0.0697  0.2546  0.0994  0.1656  0.2886  0.2060  0.1851  
Palmitoleate 0.0796  0.6073  0.0849  0.5836  0.0637  0.6851  0.1299  0.4064  0.1003  0.5221  
Inositol -0.1541  0.3180  -0.1675  0.2771  -0.1757  0.2598  -0.2557  0.0980  -0.2689  0.0812  
Dopa 0.2440  0.1104  0.2443  0.1100  0.2514  0.1039  0.2397  0.1216  0.3107  0.0425  
Uric acid 0.0657  0.6718  0.0582  0.7073  0.0321  0.8382  -0.0408  0.7953  0.0033  0.9831  
N-α-Acetyl-L-lysine_2 0.2555  0.0942  0.2614  0.0865  0.2368  0.1262  0.1556  0.3190  0.2302  0.1375  
Heptadecanoate 0.0703  0.6502  0.0671  0.6652  0.0361  0.8183  0.0637  0.6851  0.1112  0.4777  
Kynurenine -0.0766  0.6213  -0.0787  0.6117  -0.0762  0.6272  0.0268  0.8647  0.0621  0.6926  
Cystathionine 0.0973  0.5300  0.0940  0.5438  0.1130  0.4705  0.1665  0.2858  0.1481  0.3431  
Cystamine 0.2797  0.0659  0.2764  0.0693  0.2732  0.0763  0.3572  0.0187  0.4166  0.0055  
Tryptophan 0.0606  0.6959  0.0478  0.7578  0.0226  0.8858  -0.0229  0.8841  -0.0463  0.7683  
Elaidic acid 0.1914  0.2132  0.2077  0.1762  0.2010  0.1962  0.2644  0.0867  0.2952  0.0547  
Homocysteine 0.0591  0.7032  0.0516  0.7393  0.0561  0.7207  0.1409  0.3673  0.1526  0.3286  
Spearman’s rank correlation coefficients (rs) were calculated for the relationships between each dose of prednisolone (N=44); current dose or total dose including 0 mg within 1, 3, 6 months or 1 
year, and all metabolites detected by GC-MS in the sera of UCr. All samples were evaluated about only salicylates but not immunomoduratory agents and biological agents. 
 
 
 
 
 
 
 
 
Supplemental Table 14. Characteristics of the UC patients in food restriction therapy group and non-food restriction therapy group. 
  food restriction therapy non-food restriction therapy P value 
N (male/female) 4(1/3) 4(1/3) - 
Age a) 34.2±18.3/13-51 29.2±8.1/22-41 0.1824 
BMI a) 17.8±2.4/15.0-20.4 22.9±8.2/18.4-34.7 0.3173 
Disease location 
   
UC: P/LS/PC 0/0/4 1/2/1 - 
Disease activity 
   
CAI a) 8.3±1.3/7-10 8.5±1.3/7-10 0.2260 
remission/active 0/4 0/4 
 
food restriction therapy 
   
duration (days) a) 9.5±8.5/3-21 - - 
Daily medication 
   
5-Aminosalicylates 
   
Pentasa a) 3750±500/3000-4000 4000±0/4000 0.4795 
Asacol a) 0±0 3600±0/4000 - 
SASP a) 0±0 0±0 - 
Predonisolone a) 0±0 0±0 - 
6-Mercaptopurine a) 0±0 0±0 - 
Azathioprine a) 0±0 0±0 - 
Tacrolimus a) 0±0 0±0 - 
Anti-TNF-α agents a) 0±0 0±0 - 
a): Age, BMI, disease activity, days with food restriction therapy and current dose of medication are shown as the mean ± 
standard deviation together with the range. P: proctitis, LC: left-sided colitis, PC: pan-colitis, CAI: Rachmilewitz index (a clinical activity 
index). P-values were calculated using the Wilcoxon rank sum test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 15. Comparison of the serum levels of all metabolites detected by GC-MS between food restriction therapy group 
and non-food restriction therapy group 
  F.I. P-value 
  
food restriction therapy 
/non-food restriction therapy 
food restriction therapy 
vs. non-food restriction therapy 
Pyruvate+oxalacetic acid 1.4  0.0668  
Lactic acid 1.0  0.4047  
Glycolic acid 0.8  1.0000  
Alanine (2TMS) 1.5  0.0668  
Hydroxybutyrate 1.9  0.4047  
Oxalate 1.5  0.4047  
Sarcosine 0.9  0.1336  
2-Aminoisobutyrate 1.0  0.4047  
3-Hydroxybutyrate 6.0  0.4047  
2-Aminobutyric acid 1.9  0.4047  
Ketoisoleucine_1 1.0  0.2433  
Malonic acid 0.9  0.8676  
3-Hydroxyisovaleric acid 10.7 0.4047  
Valine (2TMS) 1.0  0.4047  
Urea 0.8  0.6171  
Oxamic acid 1.2  0.1336  
2-Aminoethanol 1.7  0.1336  
n-Caprylic acid 1.0  1.0000  
Phosphate 1.4  0.2433  
Glycerol 0.5  0.2433  
Ethylmalonic acid 0.7  0.6171  
Isoleucine 1.1  0.8676  
Threonine (2TMS) 1.1  0.6171  
Proline 1.0  0.8676  
Maleic acid 1.0  0.8676  
Glycine (3TMS) 1.5  0.2433  
Succinic acid (or aldehyde) 1.5  0.1336  
Catechol 1.0  0.8676  
Glyceric acid 1.5  0.6171  
Uracil 1.1  0.8676  
Fumaric acid 1.4  0.8676  
Serine (3TMS) 1.7  1.0000  
Nonanoic acid (C9) 1.3  0.1336  
4-Methylbenzoic acid 0.7  0.2433  
Glutaric acid 1.1  1.0000  
Maleamic acid 0.8  0.6171  
Prolinamide 0.7  0.6171  
Homoserine 0.9  1.0000  
Malic acid 2.2  0.2433  
Threitol 0.6  0.1336  
meso-Erythritol 1.2  0.8676  
Adipic acid 0.8  0.8676  
Acetylsalicylic acid 0.9  0.8676  
Aspartic acid 1.2  0.6171  
Methionine 1.6  0.1336  
trans-4-Hydroxy-L-proline 1.1  1.0000  
4-Aminobutyric acid 2.3  0.0668  
Pyrogallol 1.1  0.8676  
Creatinine 1.6  1.0000  
Acetoacetic acid 0.9  1.0000  
β-Glutamic acid 0.7  0.6171  
Glutamic acid 2.3  0.6171  
Phenylalanine 1.6  0.2433  
5-Aminovaleric acid 1.3  0.6171  
p-Hydroxybenzoic acid 4.8  0.4047  
Xylose_2 0.3  0.8676  
threo-β-Hydroxyaspartic acid 0.9  0.4047  
Lyxose_2 1.0  0.1336  
Arabinose 1.2  0.8676  
Lauric acid 1.4  0.0668  
N-Acetyl-L-aspartic acid_2 0.8  0.8676  
Homocysteine_1 0.9  0.8676  
Ribose 2.0  0.0668  
Ribulose 1.3  0.1336  
Asparagine 1.3  0.4047  
Taurine 3.0  1.0000  
Cysteine sulfonic acid 0.9  0.6171  
Xylitol 1.2  0.6171  
1,6-Anhydroglucose 0.4  0.6171  
Arabitol 1.0  0.1336  
Ribitol 1.4  0.4047  
Aconitate 1.0  1.0000  
N-Acetyl-L-glutamate_1 1.1  0.2433  
Glutamine 1.2  0.6171  
4-Hydroxymandelate 1.1  0.8676  
Dihydroorotate 0.8  0.8676  
O-Phosphoethanolamine 1.0  0.8676  
Theanine_2 0.9  0.6171  
Glycyl-glycine_1 0.8  0.4047  
Citric acid + isocitric acid 1.7  0.2433  
Ornithine 1.2  1.0000  
Hypoxanthine 2.1  0.1336  
Citrulline 0.9  0.2433  
1,5-Anhydro-D-glucitol 0.9  0.4047  
Tagatose_2 (or psicose_2) 0.7  0.8676  
Fructose_1 1.5  0.8676  
2-Dehydro-D-gluconate_1 2.1  0.2433  
Glucose_1 0.9  0.8676  
Sebacic acid 1.8  0.0668  
Galactose_2 2.1  0.2433  
Mannitol 1.2  0.6171  
Lysine (4TMS) 1.0  0.2433  
Galactosamine_1 1.2  0.8676  
Histidine 1.0  0.0668  
Glucuronate_1 1.2  0.2433  
5-Keto-D-gluconate_2 0.7  0.8676  
Galacturonic acid_1 1.1  0.6171  
Tyrosine 0.9  0.4047  
Pantothenate 0.9  0.8676  
N-α-Acetyl-L-ornithine_2 0.7  0.6171  
Glucarate 0.9  0.0668  
S-Benzyl-L-cysteine_1 1.2  0.1336  
Xanthine 1.9  0.0668  
Palmitoleate 3.2  0.1336  
Inositol 1.8  0.4047  
Dopa 1.0  0.8676  
Uric acid 1.4  1.0000  
N-α-Acetyl-L-lysine_2 2.0  0.1336  
Heptadecanoate 1.0  0.8676  
Kynurenine 0.7  0.8676  
Cystathionine 1.1  0.8676  
Cystamine 0.9  0.4047  
Tryptophan 0.4  0.8676  
Elaidic acid 0.7  0.2433  
Homocysteine 1.1  0.6171  
We picked up UC patients’ samples randomly (N=8) and divided them into two groups; food restriction therapy group and 
non-food restriction therapy group which various points such as age, gender ratio, BMI, medicated condition and clinical activity were 
matched. The detail data of two groups is shown in Supplemental table 15. Values are shown as fold induction (F.I.) values, which were 
obtained by comparing the peak intensity values of food restriction therapy group patients with those of non-food restriction therapy group. 
The peak intensity values for each quantified ion have been normalized to that of 2-isopropylmalic acid as an internal standard. P-values 
were calculated using the Wilcoxon rank sum test. 
 
Supplemental Table 16. Characteristics of the CD patients in infliximab administration group and non-administration group. 
  administration group non-administration group P value 
N (male/female) 7(5/2) 7(5/2) - 
Age a) 46.5±8.8/30-58 37.2±11.3/28-53 0.2003 
BMI a) 20.9±2.3/19.6-23.5 21.6±3.0/15.5-26.3 0.3379 
Disease location 
   
CD: S/C/Both 3/1/2 3/0/4 - 
Disease activity 
   
 CDAI* a) 67.7±48.8/9.5-136.3 66.1±44.6/29.4-147.4 0.848 
 remission/active 7/0 7/0 
 
Daily medication 
   
 Pentasa a) 1500±1341/0-3000 1500±1379/0-3000 0.8915 
 Predonisolone a) 0±0 0±0 - 
 6-Mercaptopurine a) 0±0 0±0 - 
 Azathioprine a) 14.2±37.9/0-100 17.8±18.8/0-50 0.2029 
 Tacrolimus a) 
  
- 
 infliximab a) 290.3±49.1 0±0 - 
 Enteral nutrition a) 471±515/0-900 557±801/0-2100 0.8358 
a): Age, BMI, disease activity, and current dose of medication including infliximab are shown as the mean ± standard deviation 
together with the range. S: small bowel, C: colon, Both: small bowel & colon, CDAI: Crohn’s disease activity index. P-values were 
calculated using the Wilcoxon rank sum test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Table 17. Comparison of the serum levels of all metabolites detected by GC-MS between infliximab administration group 
and non-administration group 
  F.I. P-value 
  
adnimistration  
/ non-adnimistration 
adnimistration  
vs. non-administration 
Pyruvate+Oxalacetic acid 1.3  0.2774  
Lactic acid 1.2  0.0845  
Glycolic acid 1.1  0.6547  
Alanine(2TMS) 1.0  0.8480  
HydroxyButyrate 1.2  0.9491  
Oxalate 0.9  0.6547  
Sarcosine 1.0  0.4822  
2-Aminoisobutyrate 1.1  0.1102  
3-Hydroxy-Butyrate 0.6  0.1102  
2-Aminobutyric acid 1.0  0.8480  
Ketoisoleucine_1 1.1  0.5653  
Malonic acid 1.2  0.0639  
3-Hydroxyisovaleric acid 1.1  0.8480  
Valine(2TMS) 0.9  0.8480  
Urea 1.1  0.0476  
Oxamic acid 1.9  0.2248  
2-Aminoethanol 0.9  0.8480  
n-Caprylic acid 1.2  0.5653  
Phosphate 0.7  0.1797  
Glycerol 0.5  0.0476  
Ethylmalonic acid 1.0  0.9491  
Isoleucine 1.0  0.6547  
Threonine(2TMS) 1.0  0.7494  
Proline 1.0  0.6547  
Maleic acid 1.2  0.0639  
Glycine(3TMS) 1.1  0.4062  
Succinic acid(or aldehyde) 1.0  0.8480  
Catechol 1.3  0.2248  
Glyceric acid 0.9  0.2774  
Uracil 1.2  0.0639  
Fumaric acid 1.2  0.1797  
Serine(3TMS) 1.1  0.8480  
Nonanoic acid(C9) 1.1  0.5653  
4-Methyl Benzoic acid 1.2  0.0181  
Glutaric acid 1.2  0.1797  
Maleamic acid 1.2  0.1417  
Prolinamide 1.0  0.9491  
homoserine 1.1  0.5653  
Malic acid 0.9  0.7494  
Threitol 1.2  0.3379  
meso-erythritol 0.2  0.6547  
Adipic acid 1.2  0.2248  
Acetylsalicylic acid 0.8  0.4822  
Aspartic acid 1.0  0.5653  
Methionine 1.0  0.5653  
trans-4-Hydroxy-L-proline 1.0  0.9491  
4-Aminobutyric acid 0.9  0.5653  
Pyrogallol 0.9  0.0476  
Creatinine 1.3  0.0845  
Acetoacetic acid 1.1  0.2248  
β-Glutamic acid 1.0  0.9491  
Glutamic acid 0.8  0.2248  
Phenylalanine 1.0  0.7494  
5-Aminovaleric acid 1.0  0.4062  
p-Hydroxybenzoic acid 0.7  0.0845  
Xylose_2 0.8  0.3379  
threo-β-Hydroxyaspartic acid  1.2  0.3379  
Lyxose_2 1.0  0.8480  
Arabinose 1.1  0.9491  
Lauric acid 0.5  0.0845  
N-Acetyl-L-Aspartic acid_2 1.0  0.9491  
Homocysteine_1 1.2  0.0639  
Ribose 0.5  0.1417  
Ribulose 1.0  0.9491  
Asparagine 1.2  0.1797  
Taurine 1.2  0.5653  
Cysteine Sulfonic acid 1.0  0.9491  
Xylitol 1.2  0.4822  
1,6-Anhydroglucose 0.9  0.5653  
Arabitol 2.0  0.5653  
Ribitol 1.0  0.9491  
Aconitate 1.1  0.1797  
N-Acetyl-L-Glutamate_1 1.1  0.6547  
Glutamine 1.0  0.8480  
4-HydroxyMandelate 1.1  0.2248  
Dihydroorotate 1.0  0.9491  
O-Phosphoethanolamine 1.1  0.5653  
Theanine_2 1.6  0.1417  
Glycyl-Glycine_1 1.1  0.2248  
Citric acid + Isocitric acid 1.1  0.9491  
Ornithine 1.3  0.0350  
Hypoxanthine 0.6  0.1797  
Citrulline 0.9  0.5653  
1,5-Anhydro-D-glucitol 1.0  0.9491  
Tagatose_2(or Psicose_2) 1.3  0.3379  
Fructose_1 1.1  0.6547  
2-Dehydro-D-gluconate_1 291.4  0.2774  
Glucose_1 1.1  0.1102  
Sebacic acid 13.5  0.4822  
Galactose_2 0.8  0.2774  
Mannitol 3.4  0.1102  
Lysine(4TMS) 0.9  0.9491  
Galactosamine_1 1.1  0.1797  
Histidine 3.2  0.0845  
Glucuronate_1 0.7  0.2774  
5-Keto-D-Gluconate_2 1.2  0.2774  
Galacturonic acid_1 1.2  0.0639  
Tyrosine 0.9  0.7494  
Pantothenate 1.0  0.9491  
N-α-Acetyl-L-ornithine_2 1.0  0.9491  
Glucarate 1.1  0.3379  
S-Benzyl-L-Cysteine_1 10.9  0.7494  
Xanthine 0.8  0.4822  
Palmitoleate 0.3  0.0253  
Inositol 1.0  0.6547  
Dopa 1.2  0.0639  
Uric acid 1.1  0.5653  
N-α-Acetyl-L-lysine_2 0.3  0.1797  
Heptadecanoate 1.2  0.2248  
Kynurenine 0.9  0.6547  
Cystathionine 0.9  0.6547  
Cystamine 1.0  0.9491  
Tryptophan 0.6  0.1102  
Elaidic acid 1.2  0.1797  
Homocystine 1.2  0.0639  
As far infliximab, the number of CD patient’s samples was sufficient for statistical analysis, so we used CD patients’ data. We 
picked up CD patients’ samples (N=14) randomly and divided them into two groups; food restriction therapy group and non-food 
restriction therapy group which various points such as age, gender ratio, BMI, medicated condition and clinical activity were matched. 
The detail data of two groups was shown in Supplemental table 17. Values are shown as fold induction (F.I.) values, which were obtained 
by comparing the peak intensity values of administration group patients with those of non-administration therapy group. The peak 
intensity values for each quantified ion have been normalized to that of 2-isopropylmalic acid as an internal standard. P-values were 
calculated using the Wilcoxon rank sum test. 
Supplemental Table 18. Spearman’s rank correlation coefficients (rs) for the relationships between daily total calorie of enteral nutrition 
therapy and all metabolites detected by GC-MS in the sera of CD in remission. 
  rs P-value  
Pyruvate+oxalacetic acid 0.2648  0.6121  
Lactic acid -0.2648  0.6121  
Glycolic acid -0.1765  0.7379  
Alanine (2TMS) 0.7945  0.0590  
Hydroxybutyrate 0.6179  0.1911  
Oxalate -0.4414  0.3809  
Sarcosine -0.0883  0.8679  
2-Aminoisobutyrate -0.8827  0.0198  
3-Hydroxybutyrate 0.5296  0.2798  
2-Aminobutyric acid 0.8827  0.0198  
Ketoisoleucine_1 -0.0883  0.8679  
Malonic acid -0.0883  0.8679  
3-Hydroxyisovaleric acid -0.1765  0.7379  
Valine (2TMS) 0.6179  0.1911  
Urea -0.7062  0.1168  
Oxamic acid -0.3531  0.4924  
2-Aminoethanol 0.1765  0.7379  
n-Caprylic acid -0.1765  0.7379  
Phosphate 0.2648  0.6121  
Glycerol 0.5296  0.2798  
Ethylmalonic acid -0.7945  0.0590  
Isoleucine 0.3531  0.4924  
Threonine (2TMS) 0.3531  0.4924  
Proline 0.2648  0.6121  
Maleic acid -0.0883  0.8679  
Glycine (3TMS) 0.2648  0.6121  
Succinic acid (or aldehyde) 0.5296  0.2798  
Catechol -0.2648  0.6121  
Glyceric acid 0.8827  0.0198  
Uracil -0.0883  0.8679  
Fumaric acid 0.0000  1.0000  
Serine (3TMS) 0.3531  0.4924  
Nonanoic acid (C9) 0.0883  0.8679  
4-Methylbenzoic acid -0.4414  0.3809  
Glutaric acid -0.9710  0.0012  
Maleamic acid -0.2648  0.6121  
Prolinamide -0.7945  0.0590  
Homoserine -0.5296  0.2798  
Malic acid 0.0000  1.0000  
Threitol -0.7062  0.1168  
meso-Erythritol -0.5296  0.2798  
Adipic acid -0.0883  0.8679  
Acetylsalicylic acid -0.3531  0.4924  
Aspartic acid 0.0883  0.8679  
Methionine 0.7945  0.0590  
trans-4-Hydroxy-L-proline 0.2648  0.6121  
4-Aminobutyric acid 0.6179  0.1911  
Pyrogallol 0.5296  0.2798  
Creatinine -0.6179  0.1911  
Acetoacetic acid -0.4414  0.3809  
β-Glutamic acid -0.7945  0.0590  
Glutamic acid 0.6179  0.1911  
Phenylalanine 0.7062  0.1168  
5-Aminovaleric acid -0.2648  0.6121  
p-Hydroxybenzoic acid 0.6179  0.1911  
Xylose_2 0.4414  0.3809  
threo-β-Hydroxyaspartic acid -0.4414  0.3809  
Lyxose_2 0.1765  0.7379  
Arabinose -0.7062  0.1168  
Lauric acid -0.3531  0.4924  
N-Acetyl-L-aspartic acid_2 -0.7945  0.0590  
Homocysteine_1 -0.0883  0.8679  
Ribose 0.6179  0.1911  
Ribulose -0.0883  0.8679  
Asparagine 0.3531  0.4924  
Taurine -0.0883  0.8679  
Cysteine sulfonic acid -0.7945  0.0590  
Xylitol -0.0883  0.8679  
1,6-Anhydroglucose 0.7945  0.0590  
Arabitol -0.7945  0.0590  
Ribitol -0.2648  0.6121  
Aconitate -0.4414  0.3809  
N-Acetyl-L-glutamate_1 -0.5296  0.2798  
Glutamine 0.4414  0.3809  
4-Hydroxymandelate 0.0000  1.0000  
Dihydroorotate -0.7945  0.0590  
O-Phosphoethanolamine -0.5296  0.2798  
Theanine_2 0.2648  0.6121  
Glycyl-glycine_1 -0.5296  0.2798  
Citric acid + isocitric acid 0.7062  0.1168  
Ornithine 0.0000  1.0000  
Hypoxanthine 0.0000  1.0000  
Citrulline 0.7945  0.0590  
1,5-Anhydro-D-glucitol 0.6179  0.1911  
Tagatose_2 (or psicose_2) 0.2648  0.6121  
Fructose_1 0.3531  0.4924  
2-Dehydro-D-gluconate_1 -0.3531  0.4924  
Glucose_1 0.2648  0.6121  
Sebacic acid -0.6179  0.1911  
Galactose_2 -0.1765  0.7379  
Mannitol -0.1765  0.7379  
Lysine (4TMS) 0.9710  0.0012  
Galactosamine_1 0.0883  0.8679  
Histidine 0.7062  0.1168  
Glucuronate_1 0.6179  0.1911  
5-Keto-D-gluconate_2 -0.5296  0.2798  
Galacturonic acid_1 -0.0883  0.8679  
Tyrosine 0.7945  0.0590  
Pantothenate -0.7945  0.0590  
N-α-Acetyl-L-ornithine_2 -0.7945  0.0590  
Glucarate 0.1765  0.7379  
S-Benzyl-L-cysteine_1 -0.5296  0.2798  
Xanthine 0.5296  0.2798  
Palmitoleate 0.2648  0.6121  
Inositol 0.8827  0.0198  
Dopa -0.0883  0.8679  
Uric acid 0.6179  0.1911  
N-α-Acetyl-L-lysine_2 -0.5296  0.2798  
Heptadecanoate -0.1765  0.7379  
Kynurenine 0.0000  1.0000  
Cystathionine 0.8827  0.0198  
Cystamine -0.5296  0.2798  
Tryptophan 0.8827  0.0198  
Elaidic acid -0.3531  0.4924  
Homocysteine -0.0883  0.8679  
Spearman’s rank correlation coefficients (rs) were calculated for the relationships between daily total calorie including 0 kcal 
of enteral nutrition; Elental, amino acid formulation (N=6), and all metabolites detected by GC-MS in the sera of CDr. All samples were 
evaluated about only salicylates but not steroid, immunomoduratory agents and biological agents. As far steroid only, previous 
medication status of several samples is unclear because of their long disease durations and complicated treatment histories in several 
hospitals. However, we could check those of steroid within a year in our medical records reliably. Therefore, the sample not medicated 
with steroid within the range of a year was treated as a non-administrated sample.  
Supplemental Figure 1.
Supplemental Figure 1. Volcano plot of UC versus HV
Volcano plot showing the alterations in the levels of all metabolites between the UC patients and HV according to GC/MS. 
P-values obtained with the Wilcoxon rank sum test and fold change values are plotted on the y- and x-axes, respectively. 
Metabolites that met the pre-defined criteria; i.e., a p-value of less than 0.05 and a fold induction value of greater than 2.0 
are included in the gray area. We selected 22 metabolites using these criteria.
Supplemental Figure 2. 
Supplemental Figure 2. Scatterplots of the values assigned by diagnostic model A to the UC patients in the 
validation set and the CD patients
Scatterplots showing the values assigned by diagnostic model A to UC patients from the validation set and 39 CD patients 
according to their serum metabolite profiles. The figure shows that almost all of the UC patients were assigned values 
above the cut-off threshold. However, almost all of the CD patients were also assigned values above the cut-off threshold; 
i.e., were false-positives. Among the CD patients, the specificity of this model was only 0.26%, so it can not be used to 
distinguish between UC and CD.
Supplemental Figure 3.
Supplemental Figure 3. Volcano plot of UC versus CD
Volcano plot showing the alterations in the levels of all metabolites between the UC patients and CD patients according to 
GC/MS. P-values obtained with the Wilcoxon rank sum test and fold change values are plotted on the y- and x-axes, 
respectively. Metabolites that met the pre-defined criteria; i.e., a p-value of less than 0.05 and a fold induction value of 
greater than 2.0 are included in the gray area. We selected 9 metabolites using these criteria.
Supplemental Figure 4. 
Supplemental Figure 4. Scatterplots of the values assigned to UC patients from the training set and CD patients by 
diagnostic model B 
The scatterplots show the values assigned to the UC patients in the training set and 39 CD patients by diagnostic model B 
based on their serum metabolite profiles. The figure shows that almost all of the CD patients were assigned values that fell 
below the cut-off threshold. The specificity of the model at various CD disease locations; i.e., the small bowel, colon, and 
both were 100%, 100%, and 96%, respectively. This shows that diagnostic model B was able to discriminate UC from CD, 
regardless of disease location.
Supplemental Figure 5.
Supplemental Figure 5. Volcano plot of UCr versus UCa
Volcano plot showing the alterations in the levels of all metabolites between the UC patients and CD patients 
according to GC/MS. P-values obtained with the Wilcoxon rank sum test and fold change values are plotted on 
the y- and x-axes, respectively. Metabolites that met the pre-defined criteria; i.e., a p-value of less than 0.05 and 
a fold induction value of greater than 2.0 are included in the gray area. We selected 12 metabolites using these 
criteria.
